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The immune system is a complex network of interacting cells and proteins that are 
constantly protecting the host from pathogens. Lymphoid and myeloid cells are the 
cellular mediators of the immune system, and the functions of these cells are partly 
controlled by the nervous system, however the mechanisms are not understood. The 
sympathetic nervous system may play a role through a family of receptors called 
adrenergic receptors (AR). Adrenergic receptors are G-protein coupled receptors that 
mediate the actions of adrenaline and noradrenaline. These receptors are spilt into the - 
and - subtypes, which can be further divided into subtypes. While -ARs have been 
well-studied, less is known about -ARs and their roles in immune regulation. The -
ARs can be divided into the   - and   - subtypes: this project focussed on the   -ARs 
as there is evidence to suggest that they play a role in inflammatory diseases. However, 
relatively little is known about which immune cell types express   -ARs, and how they 
vary during inflammation. 
The major Aim of this project was to examine the expression of   -ARs on lymphoid 
and myeloid cells in mouse spleen and establish whether simulating an acute 
inflammatory response (bacterial lipopolysaccharide: LPS) in splenocytes would alter 
the protein expression of   -ARs.  Protocols were optimised for the multi-parameter 
labelling and analysis of mouse spleen lymphoid and myeloid cells by flow cytometry, 
and the optimisation of specific   -AR surface protein staining using BODIPY-
prazosin. Normal mouse lymphoid and myeloid populations were found to express 
varying levels of   -ARs, and that all except plasmacytoid dendritic cells (pDC) 
showed an unexpected reduction in   -AR protein expression after exposure to LPS in 
vitro. The results of this project provide preliminary evidence that except for pDC, 
iv 
lymphoid and myeloid cell populations within the spleen undergo downregulation of 
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The primary function of the immune system is to protect the host from infectious 
microbes in the external environment (Chaplin, 2010).  The pathogens encountered have 
a large spectrum of pathologic mechanisms.  The immune system therefore uses a 
complex array of protective mechanisms to control and eliminate the pathogens 
(Chaplin, 2010).  The protective mechanisms can be divided into two classes: innate 
immunity and adaptive immunity. 
Inflammation is an essential immune response utilised by the host in response to 
detrimental insults such as microbial infection, tissue damage or other harmful stimuli 
(Ahmed, 2011).  It involves a physiological process where immune cells are recruited 
and activated at compromised sites to remove any harmful stimuli and initiate the 
healing process (Ahmed, 2011).  It can become pathological resulting in a chronic 
inflammatory state due to complications in the removal of the harmful stimuli or 
development of an inappropriate immune response such as allergies or auto-immune 
diseases (Medzhitov, 2010).  Compared to the acute inflammation which is considered 
to be part of the innate immune response, chronic inflammation is mainly considered to 
be mediated by adaptive immunity with lymphocytes and antigen presenting cells being 
the predominant cell types (Medzhitov, 2008). 
The innate and adaptive immune systems interact with the central nervous system 
(CNS) and autonomic nervous system (ANS) (Pongratz and Straub, 2014).  
Noradrenaline (NAD) and adrenaline (AD) act as neurotransmitters in the CNS and 
sympathetic nervous system (SNS) (Marino and Cosentino, 2013).  The stimulation of 
the SNS brings the body into a state of raised activity and attention, usually called the 
2 
‘fight or flight’ response (Marieb and Hoehn, 2010).  The effects of AD and NAD are 
mediated by adrenergic receptors (ARs) (Marino and Cosentino, 2013).   
Adrenergic receptors are a class of G-protein coupled receptors expressed in virtually all 
tissues (Marino and Cosentino, 2013).  They are divided into two major subsets,  -ARs 
and  -ARs (Hein and Kobilka, 1997).  The  -ARs and  -ARs can be further divided 
into two subsets   - and   -ARs with their own subtypes and  -ARs can be divided 
into three subsets   -,    -,   -ARs (Michelotti, Price, and Schwinn, 2000). 
Adrenergic receptors are expressed on immune cells and appear to have a function in 
the modulation of their activity (Reviewed in Marino and Cosentino, 2013).  There is 
also evidence to suggest that the SNS may also modulate the inflammatory process 
(Pongratz and Straub, 2014; Basbaum and Levine, 1991). 
The impact and expression of  -ARs on immune cells and inflammation has been well 
studied.  In contrast, there is limited knowledge about the expression of  -ARs, 
specifically   -ARs on immune cells and their possible functions (Grisanti, Perez, and 
Porter, 2011). 
This project will attempt to establish the baseline expression of   -ARs in normal 







1.1. The Immune Response and Inflammation 
1.1.1. Overview of the Immune response 
The immune system utilises a complex array of protective mechanisms to eliminate 
pathogenic microbes to protect the host (Chaplin, 2006).  These protective mechanisms 
can be divided into three components: anatomic and physiological barriers, the innate 
immune system and the adaptive immune system (Figure 1.1). 
1.1.2.  Anatomical and Physiological Barriers 
The anatomical and physiological barriers are the first line of defence against 
pathogens.  These barriers include the skin, vigorous mucociliary mechanisms, low 
stomach pH and bacteriolytic lysozyme in tears, saliva and other secretions (Turvey and 
 
Figure 1.1 The integrated human immune system. The human immune system is split into three 
divisions.  (1) The anatomical and physiological barriers, (2) Innate immunity, (3) Adaptive immunity 





The epithelium provides a physical barrier between the internal milieu and the 
pathogens that inhabit the external environment.  The epithelium comprises the skin and 
the lining of the internal tubular structures including the gastrointestinal, respiratory and 
urogenital tracts.  The internal epithelia are known as mucosal epithelia and secrete 
fluids called mucus which contains glycoproteins called mucins (Murphy, 2011).  
Mucus has a number of protective roles.  Microorganisms which are coated in mucus 
are prevented from adhering to the epithelium and expelled outwards by the cilia found 
on the mucosal epithelium (Hsieh et al., 1993). 
1.1.3. Innate Immune System 
The innate immune system augments the protection given by the anatomical and 
physiological barriers (Janeway and Medzhitov, 2002).  The innate immune system 
relies on a few invariant receptors called toll-like receptors (TLRs), but compensates by 
targeting conserved microbial components that are shared by a large group of pathogens 
(Turvey and Broide, 2010).  A defining characteristic of the innate immune system is 
that within minutes of pathogen exposure, an inflammatory response can be generated.  
Additionally the innate system plays an important role in activating the adaptive 
immune system.  
The main mediators and cells involved in the innate immune system come from both 
haematopoietic and non-haematopoietic origin.  Haematopoietic cells involved in the 
innate immune response include macrophages, dendritic cells (DCs), mast cells, 
neutrophils, eosinophils, natural killer (NK) cells and NK T cells.  In addition to these 
cells are the non-haematopoietic cells, the epithelial cells (Turvey and Broide, 2010).  
The primary responses, mediated collectively by these cells include opsonisation, 
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phagocytosis, immune cell recruitment and inflammation (Janeway et al., 2001; 
Abrutyn et al., 1977; Gin, Brottier, and Aubertin, 1984; Turvey and Broide, 2010). 
While the innate immune response is rapid, it is limited by its inability to combat 
rapidly mutating pathogens such as viruses (Turvey and Broide, 2010).  However, the 
innate immune system has evolved to recognise microbial components that are essential 
for the viability or virulence of the pathogen called pathogen-associated molecular 
patterns (PAMPs) by the use of TLRs (Turvey and Broide, 2010).  TLRs allow for 
recognition and response to diverse microbial epitopes, which allows for the innate 
immune system to distinguish between groups of pathogens and to induce the 
appropriate cascade of effector adaptive responses (Turvey and Broide, 2010).  PAMPs 
such as lipopolysaccharide (LPS) and ssRNA are recognised by TLR 4 and 8 
respectively (Turvey and Broide, 2010).   
 
1.1.4. Adaptive Immune System 
The adaptive immune system reinforces the protection initiated by the innate immune 
system.  Although both immune systems are activated by detection of an antigen, the 
adaptive immune system is much more specific and provides a broader and fine-tuned 
ability to recognise self and non-self antigens.  The adaptive immune response is 
initiated by antigen presenting cells (APCs) which include DCs, macrophages and B 
cells (Bonilla and Oettgen, 2010; Chaplin, 2010).  These APCs traffic the antigen from 
where it has been detected to secondary lymphoid tissues such as lymph nodes and the 
spleen (Bonilla and Oettgen, 2010).  The adaptive immune system is mediated by T and 
B lymphocytes, which facilitate pathogen-specific immunologic effector pathways such 
as cytotoxicity and immunological production, generate immunological memory and 
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regulate immune homeostasis (Bonilla and Oettgen, 2010; Medzhitov, 2007).  
Compared to innate immune responses, the adaptive immune responses take longer, 
ranging from hours to days, to initiate due to the time required for the proliferation and 
differentiation of antigen-specific T and B lymphocytes (clonal expansion) (Bonilla and 
Oettgen, 2010). 
 
1.2. Overview of the Inflammatory Response 
Inflammation is a protective strategy in higher organisms which responds to detrimental 
insults such as microbial infection, tissue damage and other harmful situations (Ahmed, 
2011).  Immune cells are recruited and activated which enables the removal of harmful 
stimuli as well as the healing of damaged tissue (Ahmed, 2011).  The involvement of 
immune cells leads to the five classical symptoms of inflammation which include 
redness, swelling, pain, heat and the disturbance of function (Medzhitov, 2008). 
The inflammatory response consists of four components: inflammatory inducers, the 
sensors that detect them, the inflammatory mediators and the target tissue that is 
affected by the inflammatory mediators.  These components can vary such that 
depending on the type of infection (bacterial, viral or parasitic), an appropriate 
inflammatory response can be generated (Medzhitov, 2010).   
In injuries where infections are absent, acute inflammation assists in the healing and 
repair of the injury site by promoting tissue repair and assisting in the prevention of 
colonisation by opportunistic pathogens (Medzhitov, 2010).  The tissue damage is 
detected by tissue-resident macrophages, which induce inflammatory and healing 
responses, and pain receptors (nociceptors) that enable pain detection and sensation in 
the affected area (Medzhitov, 2010).   
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The acute inflammatory response is normally terminated when the triggering stimuli are 
eliminated, the infection is cleared and the damaged tissue has been repaired (Serhan 
and Savill, 2005).  The termination of inflammation and the transition to the 
homeostatic state is a highly active and highly regulated process.  A key event in the 
resolution of inflammation is the switch from the secretion of pro-inflammatory 
cytokines such as IL-1, IL-6 and TNF  to anti-inflammatory cytokines such as IL-10, 
TGF-  and glucocorticoids.  This broadly causes a transition from the recruitment of 
inflammatory cells such as neutrophils to the recruitment of monocytes which results in 
the clearance of debris and the initiation of tissue repair at the damage site (Medzhitov, 
2010; Ahmed, 2011). 
If the resolution of inflammation or the elimination of the triggering stimuli such as a 
persistent infection or chronic cellular injury fails for any reason, then the acute 
inflammation can transition into a state of chronic inflammation (Ahmed, 2011).  The 
chronic inflammatory stage is not beneficial to the host, with the majority of chronic 
inflammatory conditions being pathogenic in nature and the majority of the damage is 
mediated by the immune response.  Some of the common chronic inflammatory 
diseases include atherosclerosis, asthma, type 2 diabetes, rheumatoid arthritis and 






1.3. Cells and Cytokines Involved in the Inflammatory 
Response 
1.3.1.  Lymphocytes 
 
The lymphocyte population is a major contributor to both the innate and adaptive 
immune system.  The lymphocyte population is mainly comprised of the thymus-
derived cells (T-cells), bone-marrow derived cells (B-cells), and the natural killer cells 
(NK cells). 
T-cells mediate cellular immunity, along with B-cells which mediate humoral immunity 















1.3.1.1.  T cells 
 
The majority of the T-cells are comprised of two major types: Helper T-cells (TH cells) 
and cytotoxic T-cells (TC cells).  
1.3.1.1.1. Helper T cells 
 
TH cells are otherwise known as CD4
+
 T cells because they express the CD4 
glycoprotein on their cell surface (Luckheeram et al., 2012).  TH cells play a critical role 
in immune protection.  Following activation via binding of T cell receptor (TCR) to 
antigenic peptides expressed on major histocompatibility complex class II (MHC II) on 
the surface of APCs, TH cells differentiate into distinct effector TH cell subtypes which 
produce cytokines and chemokines (Luckheeram et al., 2012).  These cytokines and 
chemokines have the capacity to help B-cells make antibodies, induce macrophages to 
develop enhanced microbicidal activity, and to recruit neutrophils, eosinophils and 
basophils to sites of infection and inflammation (Zhu and Paul, 2008). 
The naive TH cells can be differentiated into a number of subtypes with the major 
subtypes being the T-helper 1 (TH1) and T-helper 2 (TH2 cells).  The other subtypes 
include T-helper 17 (TH17), follicular helper T-cells (TFH), ‘natural’ T-regulatory cells 
(nTreg), induced T-regulatory cells (iTreg), type 1 T-regulatory cells, T-helper 9 (TH9) 
(Figure 1.2) (Kaplan, Hufford, and Olson, 2015; Luckheeram et al., 2012; Roncarolo et 




1.3.1.1.1.1. Helper 1 T cell 
 
TH cells play an important role in inflammation by secreting cytokines and chemokines 
that can activate and/or recruit other cell types (Zhu and Paul, 2008).  TH1 cells mediate 
the host immune response against viral and microbial pathogens.  TH1 cells primarily 
secrete interferon-  (IFN- ), IL-2 and the pro-inflammatory cytokine lymphotoxin-  
(LT- ) in response to intracellular pathogens (Figure 1.2).  Of importance is IFN-  
which is important in activating macrophages to increase their microbicidal activity and 
IL-2 which plays an important role in both TH cell memory and Tc cell memory (Kopf et 
al., 1993; Williams, Tyznik, and Bevan, 2006; Zhu and Paul, 2008). 
 
 
Figure 1.2. Summary of TH cells functions and cytokines produced.  Each subset produces a 
unique profile of cytokines and is responsible for mediating a range of adaptive responses (Adapted 
from Zhu and Paul, 2008). 
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TH1 cells also play an important role in the activation and class-switching of 
immunoglobin G (IgG) producing B cells.  TH cells provide two types of co-stimulatory 
signals, CD40 ligand (CD40L) and cytokines (Zhu and Paul, 2008).  The interaction 
between CD40L to CD40, a receptor expressed on B cells, causes the activation of B 
cells (Noelle et al., 1992).  Under the influence of IFN- , B cells preferentially induce 
the class-switch from IgM to IgG (Murphy, 2011).  IgGs are capable of neutralising 
virus particles and toxins and activate the complement system (Vidarsson, Dekkers, and 
Rispens, 2014). 
 
1.3.1.1.1.2. Helper 2 T cell 
 
TH2 cells mediate the host defence against extracellular parasites and play an important 
role in the induction and persistence of allergic diseases (Zhu and Paul, 2008).  The 
cytokines produced by TH2 cells include IL-4, IL-5, IL-9 and IL-10, IL-13 and IL-
25/IL-17E and amphiregulin (Figure 2) (Zhu and Paul, 2008).  IL-4 is the positive 
feedback cytokine for TH2 cell differentiation and plays a critical role in the humoral 
immune response (IgE class switch) against parasitic infections and is of importance in 
allergic reactions (Zhu and Paul, 2008).  IL-5 plays an important role in recruiting 
eosinophils (Salahuddin, 1989).  IL-9 is involved in the proliferation of both TC cells 
and mast cells but also induces mucin production in epithelial cell allergic reactions 
such as asthma (Longphre et al., 1999).  IL-25/IL-17E has shown to play a role in 
enhancing the production of other cytokines including IL-4, IL-5 and IL-13 (Fallon et 
al., 2006).  This in turn creates a positive feedback cycle for the proliferation of TH2 
cells and allows for the recruitment of further eosinophils (Zhu and Paul, 2008).  
Furthermore, IL-25 is also produced by lung epithelial cells in response to allergens 
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(Angkasekwinai et al., 2007).  Thus IL-25 from epithelial cells can enhance the effects 
of the TH2 response.        
 
1.3.1.1.1.3. Helper 17 T cell 
 
TH17 cells mediate the host response against extracellular bacteria and fungi (Weaver et 
al., 2006) and have also been implicated as a mediator in auto immune diseases (Afzali 
et al., 2007; Zambrano-Zaragoza et al., 2014).  The cytokines produced by TH17 cells 
include IL-17a, IL-17f, IL-21, and IL-22 (Figure 2) (Zhu and Paul, 2008). 
 
IL-17a stimulates the production of various inflammatory cytokines including IL-6 and 
chemokines such as IL-8 (Yao et al., 1995).  IL-17a and IL-17f both recruit and activate 
neutrophils during immune responses against extracellular fungi and bacteria (Zhu and 
Paul, 2008).  IL-21 is a stimulatory factor for TH17 cells and acts as a positive feedback 
amplifier (Korn et al., 2007).  IL-21 also acts as a modulator of a variety of immune 
cells including augmenting the proliferation and function of TC cells and regulating the 
activity of NK cells (Parrish-Novak et al., 2000).  IL-21 also influences B-cells and is a 
crucial regulator of antibody production and drives the differentiation of B-cells into 








1.3.1.1.1.4. Regulatory T cells 
 
Treg cells play a critical role in maintaining self-tolerance and regulating immune 
responses.  An increase in the number of Treg cells can cause an increase in their 
suppressive function which may be beneficial in auto-immune diseases where self/non-
self recognition fails.  Treg suppressive function is mediated by both cell-to-cell contact 
and cytokines, including TGF- , IL-10 and IL-35 (Figure 2) (Zhu and Paul, 2008).   
IL-10 is an important cytokine in Treg-mediated suppression.  Treg-mediated suppression 
by IL-10 production has shown to inhibit intestinal inflammation (Asseman et al., 
1999), while deletion of the IL-10 gene in mice results in spontaneous colitis and 
enhanced lung inflammation (Rubtsov et al., 2008). 
 
1.3.1.1.2. Cytotoxic T cells 
TC cells or otherwise known as CD8
+
 T cells are lymphocytes that express the CD8 
receptor that recognises antigens that are presented on target cells by the major 
histocompatibility complex class I (MHC I), which is expressed on virtually all 
nucleated cells (Bonilla and Oettgen, 2010).  The antigens that are presented on MHC I 
are generally produced from proteins that have been translated within the cell 
(endogenous antigens) encoded by the host genome or by infecting viruses or pathogens 
that have been replicating intracellularly (Bonilla and Oettgen, 2010).  
 
TC cells are one of the effector cells of the adaptive immune system and kill target host 
cells in a contact-dependent mechanism.  TC cells must become activated before they 
can mediate cell death.  While interactions between the TCR and MHC I provide a 
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partial signal for activation, further interactions between the co-stimulatory molecule 
CD28 found on the T cell and CD80 or CD86 found on the APCs provides full 
activation (Chaplin, 2006). 
 
1.3.2.  Antigen Presenting Cells 
APCs are the initiators and modulators of the immune response and are present in large 
numbers in the skin and mucosal sites, where pathogen detection is most likely.  The 
major cell types acting as APCs are DCs, macrophages and B cells.  DCs are primarily 
located in the skin and the mucosal sites, acting as mobile sentinels.  Macrophages are 
widely distributed throughout the lymphoid organs and connective tissue (Marieb and 
Hoehn, 2010).  Macrophages are phagocytic cells that engulf microbes and particles that 
have been marked for clearance by Ig, complements or both (Chaplin, 2010). 
APCs internalise extracellular proteins and pathogens and process them into antigenic 
peptides (Chaplin, 2010).  These peptides are presented on MHC II molecules where 
interactions with TH cells can occur, leading to the initiation of TH cell immune 
responses (Banchereau et al., 2000).  It should be also noted that DCs can also process 
these antigenic peptides onto MHC I and present them to and potentially activate TC 
cells (Ackerman and Cresswell, 2003).  
B and T cells are mediators of the adaptive immune response, but their function is 
controlled by the DCs.  These cells are located in the periphery of the body and 
concentrated in the secondary lymphoid tissues (Chaplin, 2010).  T cells are directly 
stimulated by DCs; however B cells are indirectly stimulated through activation of TH 
cells. While B cells can indirectly recognise an antigen through their B cell receptors 
(BCRs) with assistance for TH cells, T cells require the antigen to be processed and 
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presented to them by an APC (Banchereau et al., 2000; Ahmed et al., 2009).  This 
occurs through an interaction between the TCR and the MHC complex found on the 
APC.  These complexes are found in two types, MHC I and MHC II. 
1.3.2.1. B cells 
Adaptive humoral immunity is mediated by immunoglobulins (Ig, also known as 
antibodies) produced by plasma cells which develop from B cells under the influence of 
signals received from TH cells and other cells, such as DCs (Bonilla and Oettgen, 2010).  
Constituting 15% of peripheral blood leukocytes, B cells are derived from 
hematopoietic stem cells in the bone marrow (Bonilla and Oettgen, 2010). 
 
B cells, in contrast to T cells, express an antigen unique BCR on the cell surface.  
Circulating B cells that have not been exposed to an antigen are termed naive B cells.  
They become activated when their BCR engages their cognate antigen.  B cells are 
active as APCs and are able to internalise and digest the antigens and present the 
peptides onto a MHC II molecule to T cells (Ahmed et al., 2009; Bonilla and Oettgen, 
2010). 
1.3.2.2. Dendritic Cells 
Dendritic cells play an important role in the interface between the innate and adaptive 
immune responses by inducing, coordinating and regulating the responses  (Banchereau 
et al., 2000).  DCs not only express MHC I and II, but also TLRs that detect PAMPs 
such as LPS (TLR 4) and viral RNA (TLR 3 and 7) (Turvey and Broide, 2010).  DCs 
act as APCs which allows DCs to activate T cells by presenting the antigen, co-
stimulatory proteins and cytokines; the naive T cell then differentiates into TH cell 
subsets – TH1, TH2, TH17 and Treg (Banchereau and Steinman, 1998). 
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DCs produce a range of cytokines and chemokines.  Studies have shown that the 
ligation of CD40, a co-stimulatory protein found on APCs required for its activation, 
causes a significant increase in IL-12 (Cella et al., 1996; Koch et al., 1996).  IL-12 is 
responsible for the development of TH1 responses (Hsieh et al., 1993).  Upon antigen 
presentation to TH cells, IL-12 production will cause the differentiation of IFN-  TH1 
cells (Hsieh et al., 1993).  IFN-  is important in stimulating macrophages to increase 
their microbicidal activity and causes the up-regulation of IL-12, which in turns 
generates more TH1 cells (Hsieh et al., 1993; Schroder et al., 2004). 
In the presence of IL-4, however, DCs will induce T cells to differentiate into TH2 cells 
which then produce IL-4 and IL-5.  These cytokines activate eosinophils and assist B 
cells into producing antigen specific antibodies (Banchereau and Steinman, 1998).  The 
production of IL-33 by DCs has been shown to also induce the production of cytokines 
associated with activated TH2 cells (Figure 1.3) (Mirchandani, Salmond, and Liew, 












Figure 1.3.  Dendritic cells influence the differentiation of helper T cells. Production of 
cytokines from dendritic cells influence the differentiation of naive TH cells into Helper 1 T 















In summary, the immune system helps protect and eliminate toxic or allergenic 
substances that are able to breach the anatomical and physiological barriers.  Once a 
pathogen, toxin or allergen has been detected by an APC, the immune response is 
initiated in an attempt to protect the host and eliminate the toxic or allergic substance 







   
 
Figure 1.4. Process of immune response to pathogens Upon detection of pathogens by APCs, the immune 
response is initated with production of cytokines and chemokines from APCs activating cells from both the 
innate (e..g neutrophils) and adaptive (e.g. T and B cells) immune systems (Adapted from Tokyo, 2010) 
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1.4. Nervous System 
 
1.4.1.  Overview of the Nervous System 
 
The nervous system is divided into two sections: the peripheral nervous system (PNS), 
with the autonomic (involuntary), somatic (voluntary) and sensory sections, and the 
central nervous system (CNS).  The autonomic PNS is divided into two major sections, 
the sympathetic (SNS) and the parasympathetic nervous system (PSNS) (Koopman et 
al., 2011; Marieb and Hoehn, 2010). The SNS and PSNS generally serve the same 
organs but cause opposite effects from each other.  The dual innervation allows for the 
body to counter balance each other’s activities to allow for optimal performance of the 
body systems (Marieb and Hoehn, 2010). 
 
Generally, the stimulation of the SNS brings the body into a state of readiness and 
raised activity called the ‘fight or flight’ response (Marieb and Hoehn, 2010).  
Physiologically, there is an increase in heart rate and blood pressure, liver 
glycogenolysis is initiated and peristalsis of the gastrointestinal tract is inhibited 
(Marieb and Hoehn, 2010; Koopman et al., 2011).  In contrast, stimulation of the PSNS 
enables the ‘rest and digest’ response.  This response enables the body to restore the 
body functions back to normal following SNS stimulation.  These responses include the 
reduction of heart rate and blood pressure, stimulation of gastrointestinal peristalsis and 





1.4.2.  Sympathetic Neurotransmitters: Adrenaline and 
Noradrenaline 
 
Adrenaline (AD) and noradrenaline (NAD) are endogenous catecholamines that 
together with dopamine represent the main catecholamines in humans (Marino and 
Cosentino, 2013).  NAD is primarily produced and released by the post-ganglionic SNS 
nerve fibres and AD is produced by chromaffin cells in the adrenal glands (Marino and 
Cosentino, 2013).  NAD and to a lesser extent AD act as neurotransmitters in the SNS 
(Marino and Cosentino, 2013).   
 
When the SNS is mobilised, NAD and AD are produced.  This is most pronounced 
when the body undergoes the ‘flight or fight’ response which is mediated by a stress 
response (Marieb and Hoehn, 2010).  
 
The peripheral actions of AD and NAD vary and they include: regulation of smooth 
muscles (in particular the contraction of blood and lymphatic vessels and relaxation of 
other smooth muscles (e.g. bronchi), cardiac function (increasing the heart rate and the 
force of the contraction) and endocrine actions (modulation of the secretion of insulin 








1.4.3.  Sympathetic Nervous System Implication in 
Inflammation 
 
There is evidence to suggest that the activation of the PNS can generate the cardinal 
signs of acute inflammation (Basbaum and Levine, 1991).  These properties of acute 
inflammation include vasodilatation (heat and redness), plasma extravasation 
(swelling), and sensitisation of nociceptors to allow for a lower threshold of pain 
(Lembeck, Donnerer, and Bartho, 1982).  Studies conducted using electrical stimulation 
of the peripheral nerves (Lembeck and Holzer, 1979) or injection of the 
neurotransmitter Substance P, which stimulates primary afferent sensory C-nerve fibres 
(Saria, 1984), showed that these signs of acute inflammation could be induced. 
 
The SNS has also been shown to be implicated in regulating the innate immune 
response.  For example, NAD has been shown to have a range of effects on the innate 
immune response including changes in cytokine levels after exposure to the bacterial 
endotoxin LPS (Elenkov et al., 2008).  It should also be noted that in chronic 
inflammatory diseases such as rheumatoid arthritis, increases in SNS activity correlate 









1.4.4.  Adrenergic Receptors 
Adrenergic receptors (ARs) are a member of the G protein-coupled receptor (GPCR) 
superfamily that mediate the actions of the endogenous catecholamines, AD and NAD 
in the SNS (Piascik and Perez, 2001). 
 
1.4.4.1. Alpha and Beta Adrenergic Receptors 
 
The ARs are divided into two subtypes: the  -ARs and  -ARs.  By the late 1980s and 
early 1990s, at least nine AR subtypes (   ,    ,    ,    ,    ,    ,   ,    and   ) had 













1.4.4.1.1. Signalling and Activation 
 
The  -AR and  -AR families both exhibit different ways of signalling through their G-
coupled protein receptors.  Catecholamines bind to   -ARs to activate Gq-protein, 
whose  -subunit then activates phospholipase C (PLC) which leads to the production of 
the secondary messengers inositol triphosphate (IP3) and diacyl glycerol (DAG) and 
mobilisation of intracellular calcium and activation of protein kinase C (PKC) (Table 
1.1) (Hein and Kobilka, 1997). 
 
  -ARs are primarily coupled to and activate Gi-protein, whose  -subunit causes a 
decrease in adenylyl cyclase (AC) activity.  AC is an enzyme which catalyses the 
conversion of ATP to cyclic adenosine monophosphate (cAMP), a secondary messenger 
used in signal transduction pathways, primarily signalling through Gs-proteins (Hardin, 
Bertoni, and Kleinsmith, 2012).  However   -ARs have also been shown to couple with 
Gs-protein and subsequently cause an increase in AC activity.  It has been suggested 
that at low agonist concentrations, the activation of   -ARs causes the decrease in 
cellular cAMP levels, while at higher agonist concentrations, the activation of   -ARs 
causes an increase in cellular cAMP level (Table 1.1) (Gyires et al., 2009; Eason et al., 
1992; Jones, Halenda, and Bylund, 1991).    
 
 -ARs are primarily coupled to and activate Gs-protein.  However, similar to the  -
ARs, the  -ARs family also show dual signalling pathways.  Studies have shown that 
the   -ARs and   -ARs also exhibit Gi-protein coupling (Table 1.2) (Chen-Izu et al., 





Table 1.1 Classification of  -ARs (Adapted from Marino and Cosentino, 2013) 
Receptor Signalling mechanism Tissue distribution Physiological function 




Phospholipase D stimulation 
Activation of protein kinase C 
Human heart, liver, 
cerebellum, cerebral cortex 
 
Human prostate and urethra 
Constriction of urethral 
smooth muscle 
Contraction of skeletal 
muscle resistance arteries 
    
 
 
Mitogen activated protein kinases  
Human spleen and kidney, 
somatic arteries and veins 
Contraction of arteries and 
veins 
    
 
Human aorta, blood vessels 
of human prostate, human 
bladder 
Constriction of arteries 
Urethral contractions 
Contraction of corpus 
cavernosum 















Phospholipase A2 stimulation 
 
Gs (adenylyl cyclase stimulation) 
Human 
Brain   spleen   kidney   
aorta = lung = skeletal muscle 
  heart = liver 








kidney  liver > brain = lung 
= heart = skeletal 
muscle  




    
 
Human brain   kidney  
 
Also found in spleen, aorta, 
heart, liver, lung, skeletal 
muscle 
Presynaptic inhibition of 









Table 1.2. Classification of  -ARs (Adapted from Marino and Cosentino, 2013) 
Receptor Signalling mechanism Tissue distribution Physiological function 









Gs (adenylyl cyclase 
stimulation) 
 
Gi/Go (guanylyl cyclase 
stimulation) 
 
Pineal gland, skeletal 
muscle, liver, superior 
cervical ganglion, heart, 
lung, adrenal cortex, 
cardiac myocytes, brain 
Increase of cardiac output 
(heart rate, contractility, 
automaticity, conduction) 
Renin release from 
juxtaglomerular cells 
Lipolysis in adipose tissue 
   Lung, lymphocytes, skin, 
liver, heart 
Smooth muscle relaxation  
Striated muscle tremor and 
glycogenolysis 
Increase of cardiac output 
Glycogenolysis and 
gluconeogenesis in liver 
Insulin secretion 
   Adipose, gall bladder  
small intestine   stomach, 




Relaxation of miometrium 
and colonic smooth muscle 
cells 
Vasodilatation of coronary 
arteries 
















1.4.4.1.2. Distribution and Function 
 
ARs are distributed across the whole body with expression of ARs in the CNS and 
virtually all peripheral tissue (Tables 1 and 2) (Marino and Cosentino, 2013; Michelotti, 
Price, and Schwinn, 2000).  ARs are involved in the control of blood pressure, 
myocardial contractility, airway reactivity as well as other metabolic and CNS functions 
(Marino and Cosentino, 2013).       
 
1.4.4.1.2.1. Respiratory System 
 
Using radioligand-binding studies, it has been shown that   -ARs are expressed in the 
respiratory tract, specifically on the airway smooth muscle cells (30-40 000 per cell), 
with the density of the   -ARs increasing in the lower respiratory tract and high levels 
in the central airways and alveolar region (Chung, 2008).  CT scanning has confirmed 
that the distribution of   -ARs is greater for small airways rather than the large airways  
(Hoffman, Chiplunkar, and Casale, 1997; Ueki et al., 1993).  Further studies have 
shown that expression of   -ARs is not limited to the airway smooth muscle cells, but 
also on lung epithelial and endothelial cells, alveolar type II cells and mast cells 
(Johnson, 2001).  However the expression of   -ARs on these cells is much lower 
compared to expression of the airway smooth muscle cells. 
 
The primary effect upon activation of   -ARs in airway smooth muscle is to induce 
bronchodilation.  While not fully understood, it is believed that cAMP produced from 
activation of   -ARs inhibits the release of intracellular Ca
2+




 entry and sequesters intracellular Ca
2+
, leading to relaxation of the airway smooth 
muscle (Johnson, 2006).  
 
There has been little research into the expression of  -ARs in the respiratory system.  
There is evidence to suggest  -AR expression in present in the human airways 
(Mukherjee and Wasserman, 1986; Beil and de Kock, 1978) with these studies showing 
that  -ARs have an influence is the constriction of the airways.   
 
1.4.4.1.2.2. Vascular System 
 
Previous studies have shown that all   -AR mRNAs are expressed on peripheral 
arteries from rats (Piascik et al., 1995; Hrometz et al., 1999)  and humans (Rudner et al., 
1999).  In rats,   -AR subtypes were detected in the medial layer of the aorta, caudal, 
femoral, iliac, renal, superior mesenteric and mesenteric resistance arteries (Hrometz et 
al., 1999).  
 
   -AR has been shown to mediate the contractile function of caudal arteries in rats 
(Hrometz et al., 1999).     -AR has been shown to mediate the contractile function of 
the aorta, femora, iliac and the superior mesenteric artery (Hrometz et al., 1999).   
Studies have also used transgenic mice to assist in the explanation of the function of   -
ARs in smooth muscle.  The deletion of the    -AR gene resulted in a decrease of mean 
arterial blood pressure in response to an    agonist (45%) compared to wild type mice 
(Cavalli et al., 1997).  This indicated that    -AR is a mediator of the blood pressure 
and contractile responses (Cavalli et al., 1997).  However, these results are contradicted 
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by another study, whereby overexpression of    -AR gene did not cause a change in 
blood pressure (Zuscik et al., 2001). 
 
1.4.4.1.2.3. Cellular Signalling Pathways 
  -AR is known to regulate hypertrophic growth responses with these receptors being 
linked to mitogen activated protein kinases (MAPKs), also known as extracellular 
signal-regulated kinase (ERK).  MAPKs are protein kinases that are involved in 
signalling transduction pathways that control intracellular responses to a variety of 
events including acute responses to hormones and major developmental changes in 
organisms (Pearson et al., 2001).  MAPKs regulate cell functions including 
proliferation, gene expression, differentiation, mitosis and apoptosis (Pearson et al., 
2001).  The activation of MAPK is also important in the pathway for the activation of 
immune cells.  Many proteins including transcription factors that regulate the 
production of cytokines are targeted by MAPKs (Guha and Mackman, 2001; Kavelaars, 
2002).    
There is evidence to suggest that    -AR is involved in mediating hypertrophic 
responses in cardiac myocytes (Varma and Deng, 2000; Knowlton et al., 1993).  The 
role of the other   -AR in regulating growth promoting responses is less well studied.  
   -AR has been shown to promote MAPK activity and mediates the hypertrophic 
growth of rat aortic smooth muscle cells (Xin et al., 1997).  
   -AR has also been shown as a potential mediator of hypertrophic growth.  
Transgenic mice constitutively expressing    -AR in the cardiac tissue demonstrated 
cardiac hypertrophy (Milano et al., 1994).  Similar studies showed that mice over 
expressing    -AR transgenic mice displayed signs of cardiac hypertrophy that was 
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characterised by an increased thickness in interventricular septum and posterior wall 
and an increased isovolumetric relaxation time (Zuscik et al., 2001). 
 
1.5. Adrenergic Signalling and the Immune System 
1.5.1.  Interactions Between the SNS and Immune System 
 
It has been generally accepted that the immune system is regulated by at least two 
different neurohormonal systems: (1) hypothalamic-piturary-adrenal axis, and (2) the 
SNS (Bellinger and Lorton, 2014).  The primary (bone marrow and thymus) and 
secondary (spleen and lymph nodes) lymphoid organs are innervated primarily by the 
SNS efferent nerves, which provide a major pathway for the brain to regulate immune 
function and tissue repair (Bellinger et al., 2006).     
 
1.5.1.1. Bone Marrow 
 
The regulation of haematopoiesis and lymphopoiesis is mediated by the nerves within 
the bone marrow (Bellinger et al., 2006).  SNS nerves are in close proximity with 
hematopoietic and stromal cells in the bone marrow (Tabarowski, Gibson-Berry, and 
Felten, 1996; Felten et al., 1985).  A study of bone marrow using electron microscopy 
discovered that efferent nerve terminals are distributed between the periarterial 
adventitial (PAA) cells, a type of stromal cell that is an important source of growth 
factors (Yamazaki and Allen, 1990).  It was also discovered that these efferent nerves 
also appear in sinus PAA cells, which form a gap junction for the bone marrow stromal 
cell and the efferent nerve terminals (Yamazaki and Allen, 1990).  The close spatial 
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relationship between the nerves and the haematopoietic and stromal cells in the bone 
marrow suggests a role of the SNS in haematopoiesis (Bellinger et al., 2006).   
 
There is also evidence to suggest that a suppressive effect is exerted by the SNS on 
specific bone marrow subpopulations during acute stress by  -AR stimulation (Dresch 
et al., 1981; Beckman, Mirand, and Fisher, 1980).  Likewise for  -ARs, there is 
evidence to suggest that stimulation of   -ARs on bone marrow cells can suppress 
myelopoiesis and enhance lymphopoiesis (Reviewed in Maestroni, 1995). 
 
1.5.1.2. Thymus  
The thymic sympathetic nerves arise from the stellate ganglia and other small ganglia of 
the thoracic SNS chain (Bulloch and Pomerantz, 1984).  The SNS nerves enter the 
thymus as dense nerve plexuses with blood vessels and are primarily found in the 
medulla. The SNS nerves exit the plexuses to the parenchymal regions of the cortex 
where the nerves are situated with the stromal cells and thymocytes (Tollefson and 
Bulloch, 1990; Bulloch and Pomerantz, 1984; Bellinger et al., 2006).   
 
Radioligand studies and Northern blot analysis suggests that   -AR are expressed on 
thymic cell membranes (Marchetti et al., 1994).  Radioligand studies and RT-PCR 
studies have also shown that thymic epithelial cells, which are important in the process 
of negative and positive selection in the thymus, also express   - and   -ARs (Kurz et 
al., 1997). 
In general there are limited studies on the expression of  -AR on thymocytes.  
Immunohistochemistry and flow cytometry studies provide evidence of expression of 
  -AR expression on thymic cells (Pesic et al., 2009).  Pharmacological studies using 
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  -AR agonists indicate that   -AR expression is also present in thymic cells (Cupic et 
al., 2003; Colic et al., 2000).  
 




The expression of  -ARs on lymphocytes has been well studied.  It has been well 
established that T cells express less  -AR than B cells (Bidart et al., 1983).  Studies 
have shown that B cells express greatest number of  -ARs, followed by TC cells and TH 
cells (Karaszewski et al., 1990).  It was then reported that CD8
+ 
suppressor T cells 
expressed more  -AR than TC cells (Karaszewski et al., 1991). 
 
Stimulation of  -AR on lymphocytes may also result in the stimulation of immunity.  
Noradrenaline may promote DC production of IL-12 that mediates differentiation of 
naive TH cells into TH1 cells and increase the amount of IFN-  produced by TH1 cells 
(Swanson, Lee, and Sanders, 2001).  In B cells, the production of IgE and IgG1 
increased when NAD was added either post exposure to antigen (TNP) or within 24 
hours of culture with TH2 cells (Kasprowicz et al., 2000). 
1.5.2.1.2. Alpha-ARs 
Little data exists regarding the expression of  -ARs on lymphocytes.  Ligand binding 
studies have suggested that there is expression of   -ARs in TH and TC cells, as well as 
their up-regulation upon exposure to AD (Jetschmann et al., 1997).  However, it can be 
concluded that T cells do express both   -ARs and   -ARs.  mRNA studies have 
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shown that T cells expressed both   -ARs and   -ARs mRNA.  It was also shown that 
the expression of the mRNA was significantly higher upon exposure to Con-A, a T cell 
stimulator, than compared to baseline expression (Bao et al., 2006).  Results from the 
same study also demonstrated that the stimulation of   -ARs did not significantly affect 
T cell proliferation and IFN-  and IL-4 production.  However, stimulation of   -ARs 
did suppress T cell proliferation as well as pro- and anti-inflammatory cytokine 
production.            
 
There has been limited studies about the expression of   -ARs in B cells and there are 
no current studies to suggest that there is specific expression of   -ARs on B cells 




In studies of  -ARs expression on monocytes, it was shown that the  -AR density on 
monocytes was about 2400 binding sites/cell, and this further increased to 3220 binding 
sites/cell after physical exercise (Ratge et al., 1988).  There is some evidence to suggest 
that the density of  -ARs on monocytes changes during different stages of maturation.  
Indeed, during the maturation of monocytes to macrophages in vitro, there is a loss in  -
AR responsiveness and function to  -AR agonists (Baker and Fuller, 1995).  This could 
also explain why  -AR agonists lack significant anti-inflammatory effects on alveolar 
macrophages or in clinical asthma (Ezeamuzie, Shihab, and Al-Radwan, 2011). 
 
Activation of  -ARs on monocytes usually generates anti-inflammatory effects 
including: the inhibition of oxygen radical production (Schopf and Lemmel, 1983), up 
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regulation of tumour necrosis factor (TNF) receptors and a reduction in TNF production 
and the inhibition of LPS induced macrophage inflammation protein-1  (MIP-1 ), 
which has an important role in the development of inflammatory responses during 
infections by regulating leukocyte trafficking and function (Li et al., 2003).  It is 
interesting to note that upon activation of   -AR, the addition of LPS or IL-1 causes the 
stimulated monocytes to increase the production of the inflammatory cytokine IL-8.  It 
also however enhanced the production of the anti-inflammatory cytokine IL-10 
(Kavelaars et al., 1997). 
 
RT-PCR studies have shown that the human monocytic cell line, THP-1, expresses 
mRNA for    - and    -AR subtypes (Heijnen et al., 2002).  The expression of    -
AR was only detectable when the pro-inflammatory cytokines TNF-  and IL-1  were 
added to the cell culturing media.  It is interesting to note that other reports using the 
THP-1 cell line showed that none of the   -AR subtypes are expressed; however, 
following exposure to dexamethasone or the   -AR agonist terbutaline,    - and    -
AR subtypes could be detected by RT-PCR (Rouppe van der Voort et al., 1999).  This 
suggests that   -AR expression levels on monocytes change according to conditions 
which may account for the variability in reporting. 
 
In regards to the functional relevance in   -AR, a study has shown that in LPS 
stimulated human monocytes, the selective   -AR agonist phenylephrine can induce the 
pro-inflammatory cytokine IL-1  production.  The production is inhibited when a 
selective   -AR antagonist or inhibitors of PKC are applied (Grisanti et al., 2011).  
Similar results were also seen when the non-selective   -AR agonist isoproterenol was 
added to LPS stimulated human monocytes causing an increase in IL-1 .  The 
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application of a selective   -AR antagonist inhibited the production of IL-1  (Grisanti 
et al., 2010). 
 
1.5.2.3. Dendritic Cells 
 
There is evidence to suggest that there is expression of ARs on DCs.  Immature murine 
DCs express    -AR mRNA that is lost upon DC maturation in the lymph nodes 
(Maestroni, 2000).  It is suggested that    -AR controls DC migration due to the release 
of NE from lymph nodes influencing the migration of the immature DCs. 
 
In Langerhans cells, DCs that are located in the skin and mucosa express    -,   -, and 
  -AR mRNA (Seiffert et al., 2002).  It was discovered in the study that EP or NE 
inhibited the antigen presenting ability of the Langerhans cells.  This inhibition was 
however blocked by a   -AR antagonist, but not by an  -AR antagonist. 
 
While many studies have been performed on murine DCs, very little work has been 
carried out on humans.  One study examined the activation of   -ARs by   -AR 
agonists on human DCs that had been stimulated by either LPS or CD40-CD40L 
interactions.  It was discovered that IL-12 production is inhibited via increased cAMP 
levels, therefore inhibiting the development of TH1 cells while promoting TH2 cell 
differentiation (Panina-Bordignon et al., 1997).   
 
There seems to be extensive evidence to suggest that ARs on murine DCs influence the 
DC-T cell interactions and thus contributes to the modulation of the adaptive immune 
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response (Manni and Maestroni, 2008; Maestroni, 2006; Manni, Granstein, and 
Maestroni, 2011). 
 
1.6. Adrenergic Signalling in Inflammatory Diseases 
1.6.1.  Asthma 
 
Asthma is characterised by recurrent symptoms of airway obstruction, bronchial 
hyperresponsiveness and with evidence of chronic inflammation, which can be reversed 
spontaneously or after the use of medication.  It is the most common paediatric chronic 
inflammatory airway disease worldwide (Raedler et al., 2015).  While there is a variety 
of asthma phenotypes, clinical asthma is classed broadly into two categories, allergic 
asthma (AA) and non-allergic asthma (NA), with the former being the most prevalent 
especially in children (Agache et al., 2012; Romanet‐Manent et al., 2002). 
AA is characterised by eosinophilic airway inflammation that has specific sensitisation 
to various antigens and increased levels of IgE and blood eosinophil count.  TH2 
cytokines are the major drivers of AA with increases in IL-5 and IL-4/IL-13 (Agache et 
al., 2012; Raedler et al., 2015; Romanet‐Manent et al., 2002).  The increased numbers 
of eosinophils can be attributed to the increase in IL-5 secretion, with the increased 
proliferation and activation of eosinophils mediated by IL-5.  IL-4 and IL-13 share the 
same activity in class switching B cells to IgE production and activating monocytes and 
macrophages and increasing the production of airway mucus through goblet cell 
hyperplasia (Robinson, 2010; Wills‐Karp, 2004).  The increase in production of mucus 
in respiratory epithelial cells is also thought to be a consequence of increased allergen-
induced IL-9 secretion (Longphre et al., 1999). 
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The cytokines secreted by the airway epithelium, including IL-25, IL-33 and thymic 
stromal lymphopoitin, might also be an important driver of AA (He and Geha, 2010; 
Robinson, 2010).       
There is evidence to suggest that the expression of   -AR maybe essential in the 
pathogenesis of asthma (Davis, Paget, and Turi, 1985).  Studies have shown that   -AR 
hypersensitivity is a common feature in asthmatic patients (Davis, Paget, and Turi, 
1985; Herman et al., 1990).  However, this remains controversial (Islami et al., 2014).    
 -AR expression in asthma has been more well studied compared to  -ARs.  There is 
evidence to suggest that the expression of  -AR is increased in asthmatic airway 
smooth muscle but these receptors are uncoupled, leading to functional 
hyporesponsiveness (Reviewed in Bai, 1992).  Defects in the   -AR gene while not the 
primary cause of asthma may play an accessory role in the pathogenesis of asthma 
(Reihsaus et al., 1993).  It has been shown that a glutamine 27   -AR polymorphism is 
associated with increased levels of IgE in asthma (Dewar et al., 1997). 
 
1.6.2.  Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised 
by persistent synovitis, systemic inflammation, auto-antibodies (such as the rheumatoid 
factor), citrullinated peptides, immune cell infiltration and cartilage destruction (Scott, 
Wolfe, and Huizinga, 2010; Uysal et al., 2009). 
The synovial and cartilage cells are the cells predominantly affected by RA (Scott, 
Wolfe, and Huizinga, 2010).  The synovial cells can be divided into two groups, the 
fibroblast-like and the macrophage-like synoviocytes.  It is suggested that the over 
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production of pro-inflammatory cytokines is predominantly mediated by the 
macrophage-like synoviocytes.  The fibroblast-like synoviocytes also display abnormal 
behaviour (Scott, Wolfe, and Huizinga, 2010; Feldmann, Brennan, and Maini, 1996a).  
Studies suggest that the fibroblast-like synoviocytes infiltrate the cartilage and this 
abnormal behaviour correlates with the joint destruction associated with RA (Müller-
Ladner et al., 1996; Tolboom et al., 2005).  
The over production and over expression of TNF- , IL-1 and IL-6 appear to mediate 
RA (Feldmann, Brennan, and Maini, 1996b).  The interaction between T and B cells, 
synovial-like fibroblasts and macrophages leads to the production of such pro-
inflammatory cytokines (Scott, Wolfe, and Huizinga, 2010; Feldmann, Brennan, and 
Maini, 1996b).    
Studies conducted applying anti-TNF-  antibodies reduced the production of other 
inflammatory cytokines including IL-1, GM-CSF, IL-6 and the chemokine IL-8 
(Brennan et al., 1989).  The blocking of IL-1 using a IL-1 receptor antagonist reduced 
the production of IL-6 and IL-8 but not TNF-  (Feldmann, Brennan, and Maini, 1996a).  
Therefore it can be concluded that TNF-  appears to be an important mediator in RA 
and that pro-inflammatory cytokines are linked in a network or cascade (Feldmann, 
Brennan, and Maini, 1996b). 
There have been suggestions that neutrophils may also impact on the chronic 
inflammatory nature of RA.  Arginine deaminase 4 (AD4), an enzyme whose activity is 
dependent on the levels of extra-cellular Ca
2+
, is found in neutrophils and could be 
released when the neutrophils die or become activated.  It was found that AD4 regulates 
and creates citrulline in proteins (Andrade et al., 2010; Cooper, Palmer, and Chapple, 
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2013).  It is interesting to note that the presence of citrullinated proteins is associated 
with RA (Uysal et al., 2009). 
The role of ARs in RA in general is not very clear with more research into  -AR than 
compared to  -ARs.  With the majority of  -ARs expression on innate immune cells 
(Bellinger et al., 2008), it is interesting to note that RA patients with high disease 
activity demonstrated   -AR expression on their lymphocytes with catecholamines 
mediating their effect through   -ARs.  It was also noted that there was a decrease in 
  -AR density (Wahle et al., 1999). 
Similar observations were found in juvenile rheumatoid arthritis (JRA), also known as 
juvenile idiopathic arthritis.  Functional   -ARs appeared to be upregulated with 
increased expression observed on the leukocytes of JRA patients when compared to 
healthy subjects who displayed no expression of   -ARs on their leukocytes (Heijnen et 
al., 1996).  Stimulation of these   -ARs resulted in increased levels of the pro-
inflammatory mediator IL-6 (Roupe van der Voort et al., 2000).       
  -ARs may play an important role in RA.    -ARs have been shown to have a role in 
the modulation of the immune response of the SNS (Levine et al., 1988; Coderre et al., 
1990; Lubahn et al., 2004) and are found to be expressed on both innate and adaptive 
immune cells (Bellinger et al., 2008). 
It was observed that the density of   -ARs on peripheral blood mononuclear cells 
(PBMC), especially TC cells and B cells, was much lower compared to healthy 
individuals (Wahle et al., 2001; Baerwald et al., 1997).  Therefore it can be concluded 
that RA PBMCs are also less responsive to NE when compared to healthy subjects.  A 
study showed that B cells from RA patients had impaired responsiveness and signalling 
to   -AR agonists (Wahle et al., 2001).  This is of importance because it has been 
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shown that changes in   -AR density plays a role in determining the cytokines 
produced by PBMCs (Wahle et al., 2005).  With decreased levels of IFN-  and IL-6 
produced, a TH2 response (humoral immune response) is favoured. 
In studies using an adjuvant-induced arthritis model in rats, the application of   -AR 
agonist prior or at the onset resulted in the worsening of the disease (Coderre et al., 
1990; Lubahn et al., 2004).  In contrast, the application of   -AR antagonists seemed to 
decrease the severity of the disease (Coderre et al., 1990).  Interestingly, the application 
of an  -AR antagonist or   -AR agonist at the onset of arthritis drastically reduced the 
severity of the disease indicating that ARs may have a role in the pathogenesis of RA 
(Lubahn et al., 2004). 
 
1.7. Summary 
The immune system is divided into two major sections, the innate and adaptive immune 
system, each with their own benefits and limitations (Chaplin, 2010).  Inflammation is a 
complex and important mechanism the immune system can utilise (Medzhitov, 2008).  
It is mediated by a variety of immune cells including APCs and TH cells (Medzhitov, 
2010).  Adrenergic receptors are member of the GPCR superfamily where they have a 
wide range of functions in virtually all tissues (Marino and Cosentino, 2013).  
Adrenergic receptors mediate the action of the endogenous catecholamines EP and NE 
transmitted by the SNS (Marino and Cosentino, 2013).  Adrenergic receptors have been 
found to be expressed on immune cells with evidence to suggest that the SNS may be 
mediating the actions of the immune response and furthermore, inflammation (Marino 
and Cosentino, 2013). Targeting ARs with agonists and antagonists can potentially 
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arrest some symptoms associated with inflammatory diseases such as 
bronchoconstriction associated with asthma and severity of disease of RA. 
 
 
1.8. Hypothesis and Aims 
While the expression of  -ARs on immune cells during inflammation has been well 
studied,   -ARs on the contrary has not (Reviewed in Marino and Cosentino, 2013; 
Reviwed in Grisanti, Perez, and Porter, 2011). 
The hypothesis of this project is inflammatory stimuli will differentially upregulate   -
AR expression on mouse lymphoid immune cells.   
The aims of this project will be to: 
1. Investigate the baseline   -AR expression on immune cells in normal mouse 
lymphoid tissue. 
2. Determine whether   -AR expression changes on immune cells after exposure 








2. Material and Methods 
Animal cadavers acquired for this project were approved by the Murdoch University 
Animal Ethics Committee (Animal ethics – cadaver notice).  All reagents used were 
prepared according to manufacturers specifications, unless indicated otherwise.  
Additional details (manufacturer and catalogue number) of the reagents are listed in 
Appendix A. 
2.1. Mice 
Pathogen-free female BALB/c mice within the age range of 9 to 14 weeks were 
obtained from the Animal Resource Centre (ARC), Murdoch, WA.  Mice were culled 
by the ARC immediately prior to tissue collection. 
2.1.1.  Tissue Collection 
Spleens from two mice for each experiment were collected aseptically and pooled to 
minimise biological variability between individual mice.  Mice abdomens were sprayed 
with 70% ethanol (EtOH) before dissection with EtOH-sterile scissors and tweezers.  
Collected spleens were stored in 5% foetal bovine serum (FBS) and Dulbecco’s 
phosphate-buffered saline (DPBS) (5% FBS in DPBS) and kept on ice until use for cell 
extraction. 
2.2. Preparation of Splenocyte Suspension 
Splenocytes were extracted from collected spleens as a cell suspension.  Each spleen 
was injected at opposite ends with 5% FBS in DPBS using a 5 mL syringe and a 25 
gauge needle.  Cells dislocated by the injected buffer were gently teased out through the 
holes made during injection.  Clumps of cells were disaggregated by syringing with the 
same needle and filtered through a cotton wool column.  The cell suspension was 
42 
initially spun at 1200 RPM for 7 minutes before the supernatant was removed by 
aspiration.  Red blood cells in the pellet were lysed in 5 mL of 1X Flow Cytometry 
Mouse Lyse Buffer for 10 minutes at room temperature.  5% FBS in DPBS was added 
in excess to stop the lysis reaction and lysates were removed by aspiration of the 
supernatant following centrifugation (same conditions as previous centrifugation). 
The resultant pellet was resuspended in 3mL of 5% FBS in DPBS before filtering 
through a nylon membrane yielding a single cell suspension of splenocytes.  The 
number of viable splenocytes present in the suspension was counted manually with an 
improved Neubauer haemocytometer, at a 1 in 10 dilution of the cell suspension with 
0.4% Trypan Blue staining solution.  After counting   100 viable cells in the middle 
square, the final concentration of viable cells in cells/mL was determined using the 
following equation: 
                   (       ⁄ )  
                           
      
                      
                         
2.2.1.  Storage 
Cell suspensions were stored in 1 mL of 5% FBS in DPBS at 4 C for up to two days for 







2.3. Cell Culturing  
2.3.1.  Splenocytes 
 
Spleens were taken from 9 – 14 week old female BALB/c mice (ARC, Murdoch, WA) 
splenocytes were extracted according to the method from section 2.2 (Preparation of 
Splenocyte Suspension) and resuspended in Roswell Park Memorial Institute (RPMI) 
media (Gibco) supplemented with 10% FBS.  The cell suspension made up to 1 106 
cells/mL at 6 mL and plated in 96 well round-bottom plates (200 L/well) (Falcon, US).  
Some of the wells also had 1 g/mL LPS (1mg/mL, Enzo) supplemented into the media.  
The cells were incubated at 37  in 5% CO2. 
Separate splenocyte cultures were phenotyped after 24 hours using antibodies which 
included the lymphocyte and myeloid panel and BODIPY FL-prazosin (BPr) (100 M, 
Life Technologies).  
2.3.2.  Cell lines 
2.3.2.1. CHO Cells 
 
Chinese hamster ovary (CHO) cells (from Chelsea Back and Linda Wijaya) are derived 
from the ovary of the Chinese hamster.  Two variants of the CHO cells were used with 
one variant being transfected with   -AR (  -CHO) and the other variant being non-
transfected (NT-CHO).  Both variants of CHO cells were cultured on DMEM/F12 
media (Gibco, supplemented with 10% FBS, 2mM glutamine.   -CHO cells were 
selected using G418, gentamycin (400 g/mL, Calbiochem).  All cells were incubated at 
37  in 5% CO2. 
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2.3.2.2. Subculturing/Passaging 
CHO cells were subcultured when the desired confluency (80%) was reached. The 
DMEM/F12 growth media was removed and the monolayer of cells was washed with 
DPBS (Sigma).  500 L of trypsin (diluted down to a 1x solution, Gibco) was added to 
the monolayer.  The flask was then incubated with the trypsin to disrupt the monolayer.  
Once the monolayer was disrupted, the cells were resuspended in DMEM/F12 growth 
media and aspirated.  The aspirated cell suspension was then aliquotted into new flasks.  
Subculturing was used routinely to maintain the cell line with a maximum of 12 
passages performed before the cells were discarded. 
2.4. Flow Cytometric Analysis of Labelled Cells 
Splenocytes collected from spleens were labelled with several fluorescent markers and 
analysed by flow cytometry. 
2.4.1.  Fluorochrome-conjugated Monoclonal Antibodies in 
Staining Panels 
Splenocytes collected were split into two groups, which were then individually labelled 
with either a lymphocyte or myeloid staining panel, of which consisted of several 
markers (Table 2.1 and Table 2.2). 
Table 2.1. Fluorochrome-conjugated monoclonal antibodies used in each staining panel 
Lymphocyte Panel Myeloid Panel 
Antibody Fluorophore Antibody Fluorophore 
CD3e APC B220 APC-Cy7 
CD4 APC-Cy7 CD11b APC 
CD8a PerCP-eFluor710 CD11c PE-Cy7 
CD19 BV510 F4/80 PerCP-Cy5.5 
CD25 BV421 Ly6GC BV510 





Table 2.2. Fluorescent reagents used in each staining panel and the respective emission 
filters used for detection. 
Panel Fluorescent reagent Clone Emission Filter 
Lymphocyte 
APC-CD3e  145-2C11  660/20 BP 
APC-Cy7-CD4 GK1.5  780/60 BP 
PerCP-eFluro710-CD8a 53.67  670 LP 
BV510-CD19 1D3  450/50 BP 
BV421-CD25 PC61   510/50 BP 
Myeloid 
APC-Cy7-B220 RA3-6B2  780/60 BP 
APC-CD11b M1/70 660/20 BP 
PE-Cy7-CD11c HL3  780/60 BP 
PerCP-Cy5.5-F4/80 BM8  670 LP 
BV510-Ly6GC RB6-8C5  450/50 BP 
BV421-MHC II M5/114.15.2   540/50 BP 
 
Table 2.2. Fluorescent reagents used in each staining panel and the respective emission filters 
used for detection. 
Panel Fluorescent reagent Clone Emission Filter Laser Line 
Lymphocyte 
APC-CD3e  145-2C11  660/20 BP 663nM 
APC-Cy7-CD4 GK1.5  780/60 BP 663nM 
PerCP-eFluro710-CD8a 53.67  670 LP 488nM 
BV510-CD19 1D3  450/50 BP 405nM 
BV421-CD25 PC61   510/50 BP 405nM 
Myeloid 
APC-Cy7-B220 RA3-6B2  780/60 BP 663nM 
APC-CD11b M1/70 660/20 BP 633nM 
PE-Cy7-CD11c HL3  780/60 BP 488nM 
PerCP-Cy5.5-F4/80 BM8  670 LP 488nM 
BV510-Ly6GC RB6-8C5  450/50 BP 405nM 
BV421-MHC II M5/114.15.2   540/50 BP 405nM 
 
 
2.4.2.  Staining of Splenocytes Using the Lymphocyte and 
Myeloid Panels 
Cells were kept on ice (  4 ) at all times during staining and flow analysis to avoid 
capping (redistribution and internalisation of surface molecules), which would interfere 
with fluorescence intensity measurements (Loor, Forni, and Pernis, 1972).  Stained 
samples were stored protected from light to prevent photobleaching.   
2.4.2.1. Optimisation of Antibody Staining by Titration 
To determine optimal staining concentrations, all antibodies were titrated on 
splenocytes as described in results.  Antibodies from the lymphocyte and myeloid 
panels were titrated in a series of serial dilutions (1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 
1:1600).  CD8a and MHC II were titrated up to 1:3200. 
The serial dilutions were prepared in FACS buffer.  Cells (1     cells) were incubated 
in 100 L of each dilution for 30 minutes on ice.  Labelled cells were then washed with 
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2mL FACS buffer to remove excess antibodies.  Unless otherwise mentioned, all cells 
were resuspended in 600 L FACS buffer for flow analysis. 
2.4.2.2. Antibody Panel Staining 
Non-specific binding between fluorochrome-conjugated mAbs and low affinity Fc 
receptors expressed on surface of cells was blocked to prevent increased background 
staining. 2 L Mouse BD Fc Block (purified rat anti-mouse CD16/32) was added to 
1     cells in 100  L FACS buffer and incubated for five mins.  Cells were then 
immediately used for staining.   
A 100 L master mix containing the antibodies from either the lymphocyte or myeloid 
staining panel was prepared and was introduced and incubated to the cell suspension for 
30 minutes.  Cells were then washed and resuspended in 700 L of FACS buffer. 
2.4.3.  Determination of Viability/Dye Exclusion Test 
Due to fluorochromes used, no viability dye was compatible in any of the staining 
panels.  In an attempt to rectify this issue, Propidium Iodide (PI) was used in a separate 
unstained sample to test for cell viability and give an accurate reading.  Trypan blue 
cells counts (as described in 2.2 Preparation of Splenocyte Suspension) were performed 
on the cell suspensions on the day of FACS staining and flow cytometric analysis to 
determine the viability of the cell population.   
2.4.4. Instrumental and Analysis Software 
Cells were analysed within a period of one day after a period of one day after labelling 
with the BD FACSCanto II flow cytometer (BD Biosciences, USA) at Murdoch 
University.   
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Data on fluorescence intensity and forward and side scatter of 300,000 - 500,000 cells 
was collected with BD FACSDiva software (BD Biosciences, USA; PC version 6.1.2).  
The data collected was analysed using FlowJo software (Tree Star Inc., USA; PC 
version 10.0.8). 
 
2.4.5.  Controls and Compensations 
Unstained controls, single stained controls and fluorescence minus one (FMO) controls 
relevant to each panel were analysed together with their respective panels.  Unstained 
controls contained cells without any fluorochrome markers.  Single stained controls 
contained cells with that had been stained with only one fluorochrome marker from the 
panels.  These cells were analysed to adjust for spillover (spectral overlap) between 
detection channels.  After gating for the positive and negative cell populations for each 
single stain, compensation matrices were generated using the compensation tool in BD 
FACSDiva and onto the FMOs and experimental samples. 
FMO controls, each comprised of every fluorochrome marker in a panel minus the one 
being controlled for, were prepared and analysed to help with the determination of 
gating boundaries.  Six FMO controls were analysed for the lymphocyte panel and 
seven FMO controls were analysed for the myeloid panel. 
2.5. Optimisation of Prazosin Blocking and BODIPY FL-
Prazosin staining by Titration 
 
To determine the optimal staining concentrations of the BODIPY FL-prazosin (BPr) 
and blocking concentrations of prazosin (1.19mM, Life Technologies), the staining 
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reagent was titrated on both transfected   -adrenergic receptors (  -AR) and non-
transfected CHO cells.  Prazosin was titrated using transfected   -CHO cells in 
combination with BPr to determine the optimal blocking concentration.  CHO cells 
were kept at on ice ( 4 ) at all times during staining and flow analysis and protected 
from light.  
  
2.6. BODIPY-Prazosin 
Transfected   -AR CHO and non-transfected CHO cells were used to titrate both the 
BODIPY-prazosin (BPr) staining and the competitive blocking of terazosin.  Serial 
dilutions resulted in BPr concentrations of 400nM, 200M, 100nM, 50nM and 25nM.  
Cells (1 106) were incubated in 100  L of each concentration for 30 minutes.  All cells 
were washed once as described in section 2.4.2.1 to remove excess BPr.  The cells were 
then resuspended in 1 mL of FACS buffer after wash for flow analysis. 
2.7. Terazosin Competitive Blocking 
 
Transfected   -AR CHO cells were used to titrate the competitive blocking of 
terazosin.  Serial dilution of terazosin resulting in concentrations of 5  M, 2.5  M, 
1  M and 500nM. Cells (1 106) were stained in two separate 20 minute incubation 
steps, the first with dilutions of terazosin and the second with pre-determined dilutions 
of BPr. 
2.8. Statistic Analysis and Graphing Software 
Numerical data for the averages of triplicates are reported as mean   standard error of 
mean (SEM).  Two sample T-tests was used to test for significant changes after cell 
stimulation with LPS.  P-values of <0.05 were considered statistically significant.  
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Statistical analysis and graphing were performed using SigmaPlot (Systat Software Inc., 




3.1. Optimising Lymphoid and Myeloid Antibody Panels on 
Murine Spleen Cells 
Before the staining reagents were used in combination for lymphocyte and myeloid 
panel staining, the optimal concentration for each conjugated monoclonal antibody was 
determined by titration on normal spleen cells and then analysis by FACS.  This was to 
ensure that each staining reagent provided a strong signal without significant non-
specific background staining, which can be caused by both cellular auto-fluorescence 
and non-specific binding.        
Two criteria were used to compare the flow data collected from each antibody titration 
to determine the optimal staining concentration: firstly, the optimal titre had to 
demonstrate minimal or no background staining, which would be evident when the 
fluorescence intensity of the negative population of each titration was compared to the 
unstained cell population from the unstained control.  Second, the optimal titre had to 
provide the best distinction between the negative and positive populations, at the lowest 
concentration possible. 
Overlaying histograms, which displayed fluorescence intensity (or otherwise termed 
geometric intensity) on the x-axis and cell count on the y axis, were used to compare the 
fluorescence profiles between dilutions and optimal staining titres based on the criteria 






3.2. Monoclonal Antibody Titrations 
3.2.1.  Optimisation of Lymphocyte Panel 
APC-CD3e mAb was used to identify cells expressing CD3e, a pan-T cell marker, on 
their surface (Chetty and Gatter, 1994).  The optimal staining titre of 2 g/mL (1:100 
dilution) for APC-CD3e was determined from a single overlaying histogram and an 
antibody titration curve (Figure 3.1a, b). 
APC-Cy7 CD4 mAb was used to identify cells expressing CD4, a primarily helper T 
cell (CD4
+
) marker, on their surface (Dialynas et al., 1983).  The optimal staining titre 
of 1 g/mL (1:200 dilution) for APC-Cy7-CD4 was determined from comparing a single 
overlaying histogram (Figure 3.2a, b). 
PerCP-eFluor710-CD8a mAb was used to identify cells expressing CD8a, a primarily 
cytotoxic T cell (CD8
+
) marker, on their surface (Ledbetter et al., 1980).  The optimal 
staining titre of 0.5 g/mL (1:400 dilution) for PerCP-eFluor710-CD8a was determined 
from a single overlaying histogram (Figure 3.3a, b). 
BV510-CD19 mAb was used to identify cells expressed CD19, a pan-B cell marker, on 
their surface (Kozmik et al., 1992).  The optimal staining titre of 2 g/mL (1:100 
dilution) for BV510-CD19 was determined from a single overlaying histogram (Figure 
3.4a, b). 
BV421-CD25 mAb was used to identify cells expressing CD25, a marker primarily 
found on activated lymphocytes, on their surface (Lowenthal et al., 1985).  The optimal 
staining titre of of 2 g/mL (1:100 dilution) was determined from a single overlaying 













Figure 3.1. APC-CD3e mAb titration. (A)  Titration curve for APC-CD3e at serial dilutions of 1:25 to 1:1600 was used 
to determine the optimal titre.  The chosen optimal titre was 1:100 dilution (indicated by the asterisk (*).  Data are 
presented as mean   SEM, n = 4. 
(B) A representative overlay histogram of cells staining positively and negatively with 1:100 dilution of APC-CD3e.  
Clear separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown 
for the dilution.  The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low 























Figure 3.2. APC-Cy7-CD4 mAb titation. (A) Titration curve for APC-Cy7-CD4 at serial dilutions of 1:25 to 1:1600 
was used to determine the optimal titre.  The chosen titre was 1:400 dilution (indicated by the asterisk (*).  Data are 
presented as mean   SEM, n = 3. 
(B) A representative overlay of cells staining positively and negatively with 1:400 dilution of APC-Cy7-CD4.  Clear 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution.  The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low 
levels of background staining. 
 
Figure 3.3. PerCP-eFluor710-CD8a mAb titration. (A) Titration curve for PerCP-eFluor710-CD8a at serial dilutions of 
1:25 to 1:1600 was used to determine the optimal titre.  The chosen titre was 1:400 dilution (indicted by the asterisk 
(*).Data are presented as mean  SEM, n = 3. 
(B) A representative overlay of cells staining positively and negatively with 1:400 dilution of PerCP-eFluor710-CD8a.  
Clear separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown 
for the dilution.  The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low 














Figure 3.4. BV510-CD19 mAb titration. (A) Titration curve for BV510-CD19 at serial dilutions of 1:25 to 1:1600 was 
used to determine the optimal titre.  The chosen titre was 1:100 dilution (indicated by the asterisk (*).  Data are presented 
as mean   SEM, n = 4. 
(B) A representative overlay of cells staining positively and negatively with 1:100 dilution of BV510-CD19.  Clear 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution.  The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low 













Figure 3.5. BV421-CD25. (A) Titration curve for BV421-CD25 at serial dilutions of 1:25 to 1:1600 was used to 
determine the optimal titre.  The chosen titre was 1:100 dilution (indicated by the asterisk (*).  Data are presented as mean 
  SEM, n = 4. 
(B) A representative overlay of cells staining positively and negatively with 1:100 dilution of BV421-CD25.  Indistinct 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution.  The unstained control (tinted curve) overlaps with the negative peaks of the dilution, demonstrating low 






3.2.2.  Optimisation of Myeloid Panel 
APC-Cy7-B220 mAb was used to identify cells expressing  B220, primarily a B 
lymphocyte marker  but also useful for identifying subsets of myeloid cells e.g. 
plasmacytoid dendritic cells (Bleesing et al., 2001).  The optimal staining titre of 
1 g/mL (1:200 dilution) was determined from a set of three overlapping histograms 
from three titrations (Figure 3.6a, b). 
APC-CD11b mAb was used to identify cells expressing CD11b, a granulocyte, 
monocytes and dendritic cell (DC) marker (Lagasse and Weissman, 1996; Gao et al., 
2003).  The optimal staining titre of 1 g/mL (1:200 dilution) was determined from a a 
 
Figure 3.6. APC-Cy7-B220 mAb titration. (A). Titration curve for APC-Cy7-B220 at serial dilutions of 1:25 to 1:1600 
was used to determine the optimal titre.  The chosen optimal titre was 1:200 (indicated by the asterisk (*).  Data are 
presented as mean   SEM, n = 3. 
(B) Overlay histogram of cells staining positively and negatively with 1:200 dilution of APC-Cy7-B220.  Clear separation 
between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for the dilution.  
The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels of 





single overlaying histogram (Figure 3.7a, b). 
PE-Cy7-CD11c mAb was used to identify cells expressing CD11c, a primarily DC 
marker but also expressed by macrophage populations, on their surface (Gao et al., 
2003).  The optimal staining titre of 1 g/mL (1:200 dilution) was determined from a 
single overlaying histogram (Figure 3.8a, b). 
PerCP-Cy5.5-F4/80 mAb was used to identify cells expressing F4/80, a primarily 
macrophage marker, on their surface (Geutskens et al., 2005).  The optimal staining titre 
of 0.5 g/mL (1:400 dilution) was determined from a single overlaying histogram 
(Figure 3.9a, b). 
 
 
Figure 3.7. APC-CD11b mAb titration. (A). Titration curve for APC-CD11c at serial dilutions of 1:25 to 1:1600 was 
used to determine the optimal titre.  The chosen optimal titre was 1:200 (indicated by the asterisk (*).  Data are presented 
as mean   SEM, n = 4. 
(B) Overlay histogram of cells staining positively and negatively with 1:200 dilution of APC-CD11b.  Indistinct 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution. The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels 
of background staining.  
 




BV510-Ly6GC mAb was used to identify cells expressing both Ly-6G and Ly-6C, 
primarily a granulocyte marker, on their surface (Lagasse and Weissman, 1996).  The 
optimal staining titre of 1 g/mL (1:200 dilution) was determined from a single 
overlaying histogram (Figure 3.10a, b). 
BV421-MHC II mAb was used to identify cells expressing MHC II, a pan-antigen 
presenting cell (APC) and B cell marker, on their surface (Ernst et al., 1988; Viville et 
al., 1993).  The optimal staining titre of 0.25 g/mL (1:800 dilution) was determined 
from a single overlaying histogram (Figure 3.11a, b). 
 
Figure 3.8. PE-Cy7-CD11c mAb titration. (A). Titration curve for PE-Cy7-CD11c at serial dilutions of 1:25 to 1:1600 
was used to determine the optimal titre.  The chosen optimal titre was 1:200 (indicated by the asterisk (*).  Data are 
presented as mean   SEM, n = 3. 
(B) Overlay histogram of cells staining positively and negatively with 1:200 dilution of PE-Cy7-CD11b.  Indistinct 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution. The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels 
















Figure 3.9. PerCP-Cy5.5-F4/80 mAb titration. (A). Titration curve for PerCP-Cy5.5-F4/80 at serial dilutions of 1:25 to 
1:1600 was used to determine the optimal titre.  The chosen optimal titre was 1:400 (indicated by the asterisk (*).  Data 
are presented as mean   SEM, n = 5. 
(B) Overlay histogram of cells staining positively and negatively with 1:400 dilution of PerCP-Cy5.5-F4/80.  Indistinct 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution. The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels 








Figure 3.10. BV510-Ly6GC mAb titration. (A). Titration curve for PE-Cy7-CD11c at serial dilutions of 1:25 to 1:1600 
was used to determine the optimal titre.  The chosen optimal titre was 1:200 (indicated by the asterisk (*)).  Data are 
presented as mean   SEM, n = 3. 
(B) Overlay histogram of cells staining positively and negatively with 1:200 dilution of PE-Cy7-CD11b.  Indistinct 
separation between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for 
the dilution. The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels 















Figure 3.11. BV421-MHC II mAb titration. (A). Titration curve for BV421-MHC II at serial dilutions of 1:25 to 1:3200 
was used to determine the optimal titre.  The chosen optimal titre was 1:800 (indicated by the asterisk (*).  Data are 
presented as mean   SEM, n = 3. 
(B) Overlay histogram of cells staining positively and negatively with 1:800 dilution of BV421-MHC II.  Clear separation 
between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for the dilution.  
The unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low levels of 










3.3. Optimisation of BPr Labelling 
Due to the unavailability of a suitable monoclonal antibody specific for mouse   -
adrenergic receptor (  -AR), the reagent BPr (otherwise known as BODIPY FL-
prazosin), a high affinity   -adrenergic receptor (  -AR) specific fluorescent 
antagonist, was used to detect   -AR (Sugawara et al., 2002).  Originally the BPr 
titrated on the spleen cells, however, staining levels were very low making accurate 
















Figure 3.12. BPr titration on spleen cells. Overlay histogram of cells staining positively and 
negatively with 50nM of BODIPY-Prazosin.  Indistinct separation between the positively (higher 
intensity) and negatively (lower intensity) stained populations was shown for the dilution. The 
unstained control (tinted curve) overlaps with the negative peak of the dilution, demonstrating low 






In order to overcome this issue, BPr was titrated on Chinese Hamster Ovary (CHO) 
cells stably transfected with   -AR and compared to non-transfected CHO cells as 
controls (see Materials and Methods).  A titration curve for BPr is shown in Figure 
3.13a.  At high concentrations of BPr (>200nM), non-specific staining was observed for 
both transfected and non-transfected CHO cells (data not shown).  However, titration of 
BPr resulted in a noticeable drop in non-specific staining of BPr on non-transfected 
CHO cells while maintaining positive staining on transfected cells.  Therefore, the 
optimal concentration for BPr to detect specific staining was determined to be 50nM 
(Figure 3.13a, b). 
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3.4. Determining the specificity of BPr for   -AR 
In order to confirm the specificity of BPr for   -ARs, unlabelled terazosin, both specific 
  -AR antagonist (Brosnan et al., 1985), were used in competitive binding assays with 
BPr on   -AR CHO cells (  -CHO) and analysed by FACS.  A positive control of 
single BPr staining was done to compare with the competitor stained cells to ascertain 
whether blocking was indeed occurring or not. 
A high positive percentage and fluorescence intensity was observed on   -AR CHO 
cells when compared to the unstained   -CHO cells (Figure 3.14a).  However, after the 
addition of the terazosin, a marked decreased in positive percentage and fluorescence 
was observed in   -CHO when compared to the unstained sample (Figure 3.14b).   
 
Figure 3.13. Specific binding of BPR on CHO cells. A) The saturation curve of specific binding of BPR on CHO cells.  
The concentration of BPR was serially diluted from 400nM to 6.25nM.  The chosen concentration was 50nM (as 
indicated by the asterisk (*)).  Data are presented as mean   SEM, n = 4.     
B) Overlay histogram of   -transfected CGO cells staining positively and negatively with 50nM BPR.  Clear separation 
between the positively (higher intensity) and negatively (lower intensity) stained populations was shown for the 
concentration of BPR.  The unstained control (tinted curve) does not overlap with the negative peak of the dilution, 







In general when working with competitors, 100x the concentration of ligand of interest 
is used in competitive binding assays.  Increasing the concentration of terazosin 
continued to reduce the fluorescence intensity of the 50nM BPr (Figure 3.15).  The 
addition of terazosin had a marked effect on the geometric mean of the BPr decreasing.  
In conclusion, 5uM of terazosin was used due to the reduction seen when compared to 
the other terazosin concentrations and the reduction seen when compared to the 50nM 
BPr positive control.   
 
Figure 3.14. Relative mean fluorescence intensity of BPR before and after terazosin blocking. A) 
Overlay histogram of CHO cells that have been stained with 50nM BPR (blue dotted line) and 50nM 
BPR   5 M of terazosin (orange line).  Clear separation between the positively (higher intensity) and 
negatively (lower intensity) stained population was seen for the 50nM BPR only.  When incubated 
with terazosin, the fluorescence intensity of the BPR overlaps the unstained (tinted curve), 
demonstrating low levels of background staining and unspecific staining. 
B) Bivariate contour plots for a single representation experiment of CHO cells stained with 50nM BPR 
before and after incubation with 5 M terazosin.  CHO cells that were BPR+ were located in the right 
half while BPR
-
 was located in the left half. 
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The competitive blocking of the   -CHO cells resulted in a significant decrease (-64.73 
  8.97%, n=3) in the geometric mean of the   -CHO cells after blocking (P < 0.001, 
n=3), averaging 136.5   1.27 compared to the non-blocked   -CHO cells with an 
average geometric mean of 440   107.87. 
Confirmation of specific binding was also observed when the geometric mean of the 
blocked   -CHO cells was compared to the unstained   -CHO cells.  The geometric 
mean of the unstained   -CHO cells averaged 138.33   1.67, which indicated that 
geometric mean of the blocked   -CHO cells was similar to the unstained (P>0.05, 







Figure 3.15. Terazosin titrations.  Titration curve for terazosin where the concentration of terazosin 
had been serially diluted from 5uM to 500nM and incubated with 50nM of BPr.  The 50nM BPr 
positive control is also shown in the dot plot.  A drop is observed once the terazosin is added.  The 




3.5. Gating for Cellular Analysis by Flow Cytometry  
3.5.1.  Initial Gating Strategy 
Gates set early in analysis were identical for all experimental conditions and used 
consistently for all sample analyses.  Cells were discriminated from cellular debris by 
gating broadly on forward scatter (FSC) and side scatter (SSC) characteristics (Figure 
3.16a).  Aggregates of cells were excluded with a doublet discriminator gate (Figure 
3.16b).  While PI could not be added to the full phenotyping panels due to compatibility 
issues with the multi-colour staining panels (see Materials and Methods), PI was added 






Figure 3.16. Initial cell gating strategy. Cellular debris and cell aggregates were excluded from analysis by 
sequential gating around cells and single cells on bivariate dot plots of A) forward scatter area (FSC-A) versus side 
scatter area (SSC-A), B) FSC-A versus forward scatter height (FSC-H).  C) While not used in the early gating 




3.5.2.  Lymphocytes 
3.5.2.1.  T cells 
Initially, T cells present in the heterogeneous cellular spleen cell suspensions were 
identified by the expression of the pan T-cell marker CD3e (Chetty and Gatter, 1994).  





) were located in the lower right quadrant (Figure 3.17a).  Gating boundaries of 
the quadrant gates were determined using CD3e and CD19 FMO controls (data not 
shown). 




 helper and CD8
+
 cytotoxic T cells present in the cell suspension were identified 
by the expression of the co-receptor CD4 (helper T cells) and CD8a (cytotoxic T cells) 
respectively.  Although CD4 and CD8a can also be expressed on non-T cells (Vremec et 
al., 2000), the analysis of these markers was restricted to CD3e
+ 
T cells in the current 
study (Figure 3.17a).   
On a contour plot of APC-Cy7-CD4 (x-axis) and PerCP-eFluor710-CD8a (y-axis), 













located respectively in the lower right and upper left quadrants (Figure 3.17B).  Gating 




Figure 3.18. Phenotyping of CD4
+
 helper T cells.  Contour plots for a representative experiment (n=3) of cells 
stained with APC-Cy7-CD4, PerCP-eFluor710-CD8a, BV510-CD19, BV421-CD25 and BPR after CD4
+
 T cell 
isolation.  A) Gating of only CD4
+




 located in the lower left 
quadrant.  B) CD4
+








 cells located 
respectively in the lower right and upper right quadrants. C) CD4
+














Figure 3.17 Isolation of T and B cells. (A) Bivariate contour plot for a representative experiment (n=3) of cells 
stained with APC-CD3e and BV510-CD19.  T and B cells were located respectively in the lower right and upper left 




 cells were located in the 
upper right quadrant. 
(B) Bivariate psuedocolour dot plot for a single representative experiment of cells stained with APC-Cy7-CD4 and 
PerCP-eFluor710-CD8a after T cells gating.  CD4
+
 helper T cells and CD8
+
 cytotoxic T cells were located respectively 















3.5.2.1.1.1. Phenotyping of CD4+ helper T cells 
Isolated CD4
+
 T cells underwent phenotyping using the lymphocyte panel to determine 
what markers were expressed.  On a bivariate contour plot of PerCP-eFluor710-CD8a 
(x-axis) versus BV510-CD19 (y-axis), only CD4
+









 cells were used in 
further analysis with a bivariate contour plot utilising of APC-Cy7-CD4 (x-axis) versus 




) were located in the upper right 




 cells were also used in further analysis with 









) were located in the upper right quadrant (Figure 
3.18c).  Utilising these contour plots, it was determined that these CD4
+
 helper T cells 










(Table 3.1).  Gating 
boundaries of the quadrant gates were determined using CD4, CD8a, CD19, CD25 and 
BPr FMO controls (data not shown). 
3.5.2.1.1.2. Phenotyping of CD8+ T cells 
Gated CD8a
+
 T cells underwent phenotyping using the lymphocyte panel to determine 
which markers were expressed.  On a bivariate contour plot of APC-Cy7-CD4 (x-axis) 
versus BV510-CD19 (y-axis), only CD8
+












 cells were used in further analysis with a bivariate contour plot 
utilising of PerCP-eFluor710-CD8a (x-axis) versus BV421-CD25 (y-axis), CD25
+
 

















 cells were also used in further analysis with a bivariate contour plot 
utilising PerCP-eFluor710 (x-axis) versus BPr (y-axis), BPr
+





) were located in the upper right quadrant (Figure 3.19c).  Utilising these contour 
plots, it was determined that these CD8
+











(Table 3.1).  Gating boundaries of the quadrant gates 






Figure 3.19 Phenotyping of CD8
+
 T cells.  Bivariate contour plots for a representative experiment (n=3) of cells 
stained with APC-Cy7-CD4, PerCP-eFluor710-CD8a, BV510-CD19, BV421-CD25 and BPR after CD8
+
 T cell 
isolation.  A) Gating of only CD8
+




 located in the lower left 
quadrant.   
B) CD8
+








 cells located 
respectively in the lower right and upper right quadrants. C) CD8
+



















) present in the heterogeneous cellular suspensions were 
identified by the expression of the pan B-cell marker CD19 (Kozmik et al., 1992).  On a 





) were located in the upper left quadrant (Figure 3.17a).  Gating 
boundaries of the quadrant gates were determined using CD3e and CD19 FMO controls 







Table 3.1.  Summary of phenotypes of normal spleen lymphocyte subsets 
Cell type CD3e CD4 CD8a CD19 CD25 BPr 
CD4
+
 T cell + + - - + low - 
CD8
+
 T cell + - + - - - 
B cell - -  + + low - 
 
3.5.2.2.1. Phenotyping of B cells 
Gated CD19
+
 B cells underwent phenotyping using the lymphocyte panel to determine 
which markers were being expressed.  On a bivariate contour plot, further analysis 














 cells were used in further analysis with a bivariate contour plot utilising 
BV510-CD19 (x-axis) versus BV421-CD25 (y-axis), CD25
+





were located in the upper left quadrant (Figure 3.20b).  On another bivariate contour 
plot utilising BV510-CD19 (x-axis) versus BPr (y-axis), BPr
+






Figure 3.20. Phenotyping of CD19
+
 B cells.  Bivariate contour plots for a representative experiment (n=3) of cells 
stained with APC-Cy7-CD4, PerCP-eFluor710-CD8a, BV510-CD19, BV421-CD25 and BPR after CD19
+
 B cell 
isolation.  A) Gating of only CD19
+




 located in the lower left 
quadrant.  B) CD19
+








 cells located 
respectively in the lower right and upper right quadrants. C) CD4
+



















) were located respectively in the upper left and lower left 
quadrants (Figure 3.20c).  Utilising these contour plots, it was determined that these B 










 (Table 3.1).  Gating 
boundaries of the quadrant gates were determined using CD4, CD8, CD19, CD25, BPr 
FMO controls (data not shown).  
3.5.3.  Myeloid Cells 
3.5.3.1. Conventional Dendritic Cells 
Conventional dendritic cells (cDCs) were initially identified by the expression of MHC 





 does not solely isolate cDCs as there is the possibility of 
plasmacytoid DCs (pDCs) having a similar phenotype in the spleen  (Ferrero et al., 
2002).  To account for this, a bivariate contour plot of APC-Cy7-B220 (x-axis) versus 




) located in the 
lower left quadrant (Figure 3.21b).   
3.5.3.1.1. Phenotyping of Conventional Dendritic 
Cells 
Conventional dendritic cells (cDCs) were initially identified by the expression of MHC 





 does not solely isolate cDCs as there is the possibility of 
plasmacytoid DCs (pDCs) having a similar phenotype in the spleen  (Ferrero et al., 
2002).  To account for this, a bivariate contour plot of APC-Cy7-B220 (x-axis) versus 




) located in the 
lower left quadrant (Figure 3.21b).  Using these contour plots, it was determined that 
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(Table 3.2).  Gating boundaries of the quadrant gates were determined using 
B220, CD11b, CD11c, F4/80, Ly6GC, MHC II and BPr FMO controls (data not 









Figure 3.21. Gating strategy and phenotyping of cDCs.  Bivariate contour plots for a representative experiment 
(n=4) of cells stained with APC-Cy7-B220, APC-CD11b, PE-Cy7-CD11c, PerCP-Cy5.5-F4/80, BV510-Ly6GC, 




 conventional DCs (cDCs) were located in the upper right quadrant.  































 cDCs show no   -AR expression with BPR
-
 cDCs located in the lower right 





Macrophages were initially identified by the expression of primary macrophage marker 
F4/80 and lack of the monocyte marker Ly6C.  On a bivariate contour plot of PerCP-





located in the upper left quadrant (Figure 3.22a). 





) underwent phenotyping using the myeloid panel 
to determine which markers were being expressed.  On a bivariate contour plot of APC-









) were located in the lower right quadrant (Figure 3.22b).  On another 


















 macrophages were located respectively in the upper left, lower right 
and upper right quadrants (Figure 3.22c). The gated macrophages were analysed for   -







) located in the lower right quadrant (Figure 3.22d).  















(Table 3.2).  Gating 
boundaries of the quadrant gates were determined using B220, CD11b, CD11c, F4/80, 
Ly6GC, MHC II and BPr FMO controls (data not shown).       
77 
 
3.5.3.3. Plasmacytoid Dendritic Cells 
Plasmacytoid dendritic cells (pDCs) were identified by the expression of B220 and 









).  On a bivariate contour plot of 




) were located in 
the upper right quadrant (Figure 3.23a).   






) underwent phenotyping using the myeloid panel to 
determine which markers were being expressed.  On a bivariate contour plot of BV421-
MHC II (x-axis) versus PE-Cy7-CD11c (y-axis), MHC II
+















 pDCs were located respectively 
 
Figure 3.22. Gating strategy and phenotyping of macrophages.  Bivariate contour plots for a representative 
experiment (n=4) of cells stained with APC-Cy7-B220, APC-CD11b, PE-Cy7-CD11c, PerCP-Cy5.5-F4/80, BV510-









 macrophages show high levels of B220 and no CD11b expression with B220
+
 macrophages and 
CD11b
-





macrophages show high levels of MHC II and CD11c expression with MHC II
+
 macrophages and CD11c
+
 
macrophages located respectively in the upper left and lower right quadrants. Double negative macrophages were 













 macrophages located in the lower right 






in the lower left, upper right and upper left quadrants (Figure 3.23b).  On another 





 pDCs were located in the upper right quadrant (Figure 3.23c). 
The isolated pDCs were analysed for   -AR using a bivariate contour plot utilising 













) located respectively in the upper right and lower right quadrants (Figure 















(Table 3.2).  
Gating boundaries of the quadrant gates were determined using B220, CD11b, CD11c, 
F4/80, Ly6GC, MHC II and BPr FMO controls (data not shown).       
 
 
Figure 3.23. Gating strategy and phenotyping of pDCs.  Bivariate contour plots for a representative experiment 
(n=4) of cells stained with APC-Cy7-B220, APC-CD11b, PE-Cy7-CD11c, PerCP-Cy5.5-F4/80, BV510-Ly6GC, 









 pDCs show high level of MHC II and CD11c expression with MHC II
+
 pDCs and CD11c
+
 pDCs 
located respectively in the lower right and upper left quadrants.  Double negative pDCs were located in the lower left 






























3.5.3.4. Phenotyping of Neutrophils 
Neutrophils were identified by the expression of primary neutrophil marker Ly6GC 
(Gumley, McKenzie, and Sandrin, 1995).  On a bivariate contour plot of BV510-







were located in the bottom right quadrant (Figure 3.24a).    





) underwent phenotyping using the myeloid panel to 
determine which markers were being expressed.  On a bivariate contour plot of BV421-
MHC II (x-axis) versus PE-Cy7-CD11c (y-axis), MHC II
+









) were located respectively 
in the lower right and lower left quadrants (Figure 3.24b).  On another bivariate contour 











) were located 
respectively in the lower right and lower left quadrants (Figure 3.24c). 
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The gated neutrophils were analysed for   -AR using a bivariate contour plot utilising 







in the lower right quadrant (Figure 3.24d).  Utilising these contour plots, it was 













   -AR
-
 (Table 3.2).  Gating boundaries of the quadrant gates 
were determined using B220, CD11b, CD11c, F4/80, Ly6GC, MHC II and BPr FMO 




Figure 3.24. Gating strategy and phenotyping of neutrophils. Bivariate contour plots for a representative 
experiment (n=4) of cells stained with -Cy7-B220, APC-CD11b, PE-Cy7-CD11c, PerCP-Cy5.5-F4/80, BV510-


















 neutrophils show low levels of CD11b 








 neutrophils located in the bottom right and upper 








 neutrophils located in 






Table 3.2. Summary of phenotypes of normal spleen myeloid cells 
Cell type B220 CD11b CD11c F4/80 Ly6GC MHC II BPr 
cDCs - - + + very low - + high - 
Macrophages + - + + - + high - 
pDCs + + int + int + low + int + + 
Neutrophils - - - + + high + - 
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3.6. Expression of  -AR on lymphocyte and myeloid cells 
after LPS exposure 
 
Fresh spleen cells were cultured in two different conditions, normal media or media 
with LPS supplemented.  The introduction of LPS was done to initiate an immune 
response.  Generally, comparisons between the non-LPS and LPS are performed.  From 
examining the unstained profiles, it could be seen that LPS had an effect on the immune 
cells with the cells become larger (higher FSC value) (Figure 3.25).  However, upon 
analysis of the data, it was observed that comparing between the two cultured 
conditions would not be possible due to insufficient activation of spleen cells.  
Statistical analysis also revealed that comparisons between non-LPS and LPS cultured 
cells would have resulted in statistically insignificant data (p>0.05, n=7) (data not 
shown).  Therefore comparisons between fresh and LPS stimulated were done. 
3.6.1.  Lymphocytes 
 
Stimulation of CD4 T cells resulted in a significant decrease (-61.501   9.988%, n=3) 
in the expression   -AR in LPS stimulated CD4
+
 T cells (p<0.05, n=3), averaging 17.1 
  3.504 compared to fresh cells with an average geometric mean of 55.908   15.338 
(Figure 3.26). 
 
Stimulation in cytotoxic (CD8
+
) T cells resulted in a significant decrease (-63.618   
10.473%, n=3) in the expression of   -AR in LPS stimulated CD8
+
 T cells (p<0.05, 
n=3), averaging 18.767   5.3 compared to fresh cells with an average geometric mean 




Figure 3.26 Comparison of geometric MFI of   -AR expression on CD4
+
 T cells after in vitro culture.  
The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining of spleen CD4
+
 T 
cells analysed either on freshly isolated cells or after in vitro culture with or without LPS for 24 hours. A 
significant decrease in expression of   -AR was detected between LPS stimulated and fresh CD4
+
 T cells 
(p<0.05).  No significant differences were detected for other conditions.  Data are presented as mean   SEM 






Figure 3.25. Comparison of unstained profiles of splenocytes stimulated and not stimulated by LPS.  
Unstained profiles of the two different culturing conditions showing cells with different FSC values.  LPS 




Figure 3.27. Comparison of geometric MFI of   -AR expression on CD8
+
 T cells after in vitro 
culture.  The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining 
of spleen CD8
+
 T cells analysed either on freshly isolated cells or after in vitro culture with or 
without LPS for 24 hours. Significant differences were detected between the fresh CD8
+ 
T cells and 
each of the experimental conditions for expression of   -AR (p<0.05).  No significant differences 
were detected between the cultured CD8
+
 T cells that had been stimulated by LPS and those that had 




Stimulation in B cells resulted in a significant decrease (-53.189   16.224%, n=3) in the 
expression of   -AR in LPS stimulated B cells (p<0.05, n=3), averaging 18.833   










Figure 3.28. Comparison of geometric MFI of   -AR expression on B cells after in vitro 
culture.  The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining 
of spleen B cells analysed either on freshly isolated cells or after in vitro culture with or without LPS 
for 24 hours. Significant differences were detected between the LPS stimulated and fresh B cells for 
  -AR expression (p<0.05).  No significant differences were detected for other conditions. Data are 
presented as mean   SEM (n=3).  * indicates p<0.05 between the LPS stimulated and fresh cells. 





3.6.2. Myeloid Cells 
Stimulation in cDCs resulted in a significant decrease (-80.582   8.477%, n=4) in the 
expression of   -AR in LPS stimulated cDCs (p<0.05, n=4), averaging 7.155   2.508 
compared to fresh cells with an average geometric mean of 33.766   10.766 (Figure 
3.29). 
Stimulation in macrophages resulted in a significant decrease (-58.513   17.773%, n=4) 
in the expression of   -AR in LPS stimulated macrophages (p<0.05, n=4), averaging 
23.9   4.54 compared to fresh cells with an average geometric mean of 90.025   
31.8723 (Figure 3.30). 
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Stimulation in pDCs resulted in an increase (26.037   54.026%, n=4) in the expression 
of   -AR in LPS stimulated pDCs.  However, the data was not significant with p>0.05 
(n=4).  An immediate explanation could not be provided.  In hindsight, the increase in 
  -AR and statistically insignificant data could have been the result of the large 
variation in the geometric mean of the fresh cells (20.695   10.347, n=4) and LPS 
stimulated cells (25.163   6.854, n=4), although this warrants further investigation 
(Figure 3.31). 
Stimulation in neutrophils resulted in a decrease (-64.831   8.313%, n=4) in the 
expression of   -AR in LPS stimulated neutrophils (p<0.05, n=4), averaging 9.725   
2.270 compared to fresh cells with an average geometric mean of 21.646   10.823 
(Figure 3.32). 
 
Figure 3.29. Comparison of geometric MFI of   -AR expression on cDC after in vitro culture.  
The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining of spleen 
cDC analysed either on freshly isolated cells or after in vitro culture with or without LPS for 24 
hours. Significant differences were detected between the fresh cDCs and each of the experimental 
conditions for expression of   -AR (p<0.05).  There were no significant differences between cDC 







Figure 3.30. Comparison of geometric MFI of   -AR expression on macrophages after in vitro 
culture.  The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining 
of spleen macrophages was analysed either on freshly isolated cells or after in vitro culture with or 
without LPS for 24 hours. Significant differences were detected between the fresh macrophages and 
each of the experimental conditions for expression of   -AR (p<0.05).  No significant differences 
were detected between the cultured macrophages that had been stimulated by LPS and those that had 
not been stimulated by LPS (p>0.05). Data are presented as mean  SEM (n=4).  * indicates p<0.05 

























Figure 3.31 Comparison of geometric MFI of   -AR expression on pDC after in vitro culture.  
The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining of spleen 
pDC analysed either on freshly isolated cells or after in vitro culture with or without LPS for 24 
hours. No significant differences were detected between any of the experiment conditions for 



















Figure 3.32 Comparison of geometric MFI of   -AR expression on neutrophils after in vitro 
culture.  The geometric mean fluorescence intensity (MFI) of BODIPY-prazosin (  -AR) staining 
of spleen neutrophils analysed either on freshly isolated cells or after in vitro culture with or without 
LPS for 24 hours. Significant differences were detected between LPS-stimulated and non-stimulated 
cultured neutrophils and fresh neutrophils for   -AR expression (p<0.05).  There were no significant 
differences between neutrophils cultured with or without LPS. Data are presented as mean   SEM 






The purpose of this study was to determine whether inflammation would upregulate the 
expression of   -ARs in populations of immune cells.  The   -ARs have known 
functions in various tissues including the regulation of contractility in smooth muscle, 
growth promoting responses and involvement in cellular signalling pathways (Piascik 
and Perez, 2001).  Recent studies on immune cells have shown that   -ARs may have a 
role in the modulation of immunity, but this is still poorly understood (Reviewed in 
Grisanti, Perez, and Porter, 2011).  While numerous studies have examined the mRNA 
level of expression, few studies have examined the protein expression during 
inflammation.  The overall aim of this study was to examine the expression of   -ARs 
of murine splenocytes upon stimulation by LPS.  The projects aim was to determine the 
baseline protein expression of   -ARs on fresh immune cells in the spleen and compare 
the expression of   -ARs on the immune cells after exposure to LPS.  It was discovered 
that the protein expression of   -ARs was lower in LPS stimulated immune cells than in 
fresh immune cells.  This decrease was seen throughout the lymphoid and myeloid cell 









4.1. Optimisation of Lymphocyte and Myeloid Staining 
Panels 
The primary technique used in this project was flow cytometry, which allows 
quantitative analysis of surface protein expression on living cells using fluorescently 
labelled monoclonal antibodies (mAbs) and other fluorescent markers.  To achieve 
optimal results, all mAbs had to be titrated first in order to determine optimal staining 
profile that would reduce non-specific staining while giving clear positive signals and 
using the least amount of antibodies.  A range of mAbs was used to identify lymphoid 
and myeloid cell subsets in mouse spleen, along with BODIPY-prazosin (BPr) to 
specifically identify   -ARs.  Antibodies that were targeted towards highly expressed 
surface markers on lymphocytes, such as CD3e, CD4, CD8a, CD19, B220 and MHC II, 
generally gave good titration profiles with clear separation of positive and negative 
peaks, and optimal dilutions could be easily determined.  However, some myeloid 
markers such as CD11c, primarily a DC marker but also expressed on some other 
myeloid cells such as neutrophils, were expressed in low levels in the spleen due to the 
spleen primarily being a site for migration of lymphocytes (Gao et al., 2003; Yang et al., 
2013).  Other markers that had low expression on splenocytes included CD11b, F4/80 
and Ly6GC (Gao et al., 2003; Zwadlo et al., 1985; Lagasse and Weissman, 1996).  As 
such, a proper titration was difficult to do for these markers.  The optimal titrations for 
these markers were determined using the line plots of the geometric mean fluorescent 
intensity (MFI) for each mAb, as well using the expression profiles by single parameter 
histogram.  In general, the optimal concentration was chosen when the first drop in 
geometric MFI was seen or when the drop in geometric MFI had become half the 
highest geometric MFI.   
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In summary, the titration of the mAbs for the lymphocyte and myeloid panels was 
successful with an optimal titre determined for all mAbs based on positive fluorescence 
intensity, low background staining and minimal antibody concentration.         
 
4.2. Optimisation of BODIPY-Prazosin binding and 
confirmation of specificity 
 
BODIPY-prazosin (BPr) was the chosen fluorescent ligand to use in this study due to its 
use in previous studies that show that BPr is specific on   -ARs (Sugawara et al., 
2002).  BPr a fluorescent analogue of the   -AR antagonist prazosin, consists of the 
BODIPY fluorescent dye and prazosin, a very specific   -AR antagonist.  Primarily a 
staining reagent, studies involving BPr are very diverse from identifying both diffuse 
and highly mobile clustered   -AR on various tissues including the endothelial cells of 
arteries to examination of   -AR on transfected cell lines (Daly et al., 1998; Sugawara 
et al., 2002; Daly et al., 2010).  However, BPr has also been used in other methods such 
as efflux studies (Robey et al., 2003; Elliott, Raguz, and Higgins, 2004).  The primary 
methods of analysis of BPr in these studies include flow cytometry and confocal 
microscopy. 
 
Staining splenocytes in an attempt to find an optimal concentration had already proved 
to be an issue in this project, as the BPr staining levels were low, and I was unable to 
determine an optimal concentration (see Results).  Similar to mAb titrations, if a high 
concentration of BPr was used to stain cells, it would have resulted in non-specific 
staining, resulting in a false positive signal.  Consequently, the titration of the BPr on 
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transfected   -Chinese Hamster Ovary (  -CHO) cells was investigated.  CHO cells are 
a commonly used cell line in molecular biology due to their low chromosome number 
and small size (Puck, Cieciura, and Robinson, 1958).    -CHO cells are CHO cells 
which have been transfected to constitutively express   -ARs. 
   
In order to determine the specificity of BPr, a competitive binding study was performed 
using terazosin.  Terazosin, an   -AR antagonist, was used as competitive blocker in 
  -CHO cells.  As the   -CHO cells express   -ARs constitutively, terazosin should 
bind to a majority of the   -ARs before the addition of BPr.  By comparing the MFI of 
  -CHO cells to the MFI of the   -CHO cells stained with BPr and MFI of the 
unstained   -CHO cells, it would be possible to determine if BPr was non-specifically 
binding to the   -CHO cells or not.  A marked decrease in MFI of the terazosin blocked 
  -CHO cells when compared to BPr stained only   -CHO cells would be indicative of 
specific binding.  If the MFI of the terazosin blocked   -CHO cells had a higher MFI to 
the unstained   -CHO cells, then it would be indicative of non-specific binding with the 
BPr potentially increasing the MFI of the terazosin blocked   -CHO cells. 
 
The same competitive binding study was performed on non-transfected CHO (NT-
CHO) cells to determine if there was any non-specific binding from the BPr because 
theoretically, there should be no   -AR expression.  Various studies utilising 
transfected CHO cells have used NT-CHO cells as a negative control; therefore for the 
purposes of this study, it was also used as the negative control (Shibata et al., 2003; 
Björk, Vainio, and Scheinin, 2005).  The BPr binding experiments on NT-CHO cells 




In conclusion, a significant reduction in the geometric MFI of BPr (p<0.001) for   -
CHO cells blocked with terazosin was observed (Figure 3.14), indicating that BPr was 
specific for   -ARs.  This conclusion was further endorsed with no non-specific 
binding on NT-CHO cells. 
 
4.3. Immunophenotyping for better resolution of cell 
populations and   -AR expression 
Utilising the lymphocyte panel which included the markers CD3e, CD4, CD8a, CD19, 













) (Kessel et al., 2012; Correale and 
Villa, 2010; de Andrés et al., 2014).  However the three populations of lymphocytes of 













).  Also of interest were the double positive populations that 
co-stained when CD4
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 T cells sticking together and being analysed at the 




 T cells do exist in normal conditions 
but their numbers increase in immuno-inflammatory conditions (Parel and Chizzolini, 









 T cells has been observed during viral infections (Nascimbeni et al., 2004).  




 T cells came to the conclusion that these T cells 
may take part in the adaptive immune response against infectious pathogens and may 
have possible immunoregulatory and/or immunosurveillance functions (Zuckermann, 
1999; Nascimbeni et al., 2004). 
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Immunophenotyping of the myeloid populations was more difficult than compared to 
the lymphocyte populations.  The myeloid panel which consisted of B220, CD11b, 
CD11c, F4/80, Ly6GC and MHC II was used to stain splenocytes.  The difficulty arose 
because myeloid cells make up a low percentage of the total composition of the spleen 
with lymphocytes being the dominant immune cell type (57.1 – 93.2%) (Yang et al., 
2013).  A study conducted on C57BL/6J mice determined that myeloid cells composed 
of 2.9 – 19.5% of the spleen (Yang et al., 2013). 

























).  The two 
subsets were separated by using B220 as the primary determinant, with B220 primarily 
expressed on pDCs and not cDCs (Ferrero et al., 2002).     
 
4.4. LPS activation of cell types 
Lipopolysaccharide (LPS) was used in cell cultures to attempt to replicate an acute 
immune response in vitro.  LPS binds to ‘toll-like receptor 4’ (TLR 4) which is found 
on numerous immune cell types.  TLR4 signalling can be divided into two pathways: 
MyD88-dependent and MyD88-independent (TRIF-dependent) (Figure 4.1). 
In the MyD88-dependent pathway, the stimulation of MyD88 results in the recruitment 
of IL-1 receptor-associated kinase (IRAK).  IRAK is activated by phosphorylation and 
associates with TRAF6 and activates TAK1.  TAK1 then activates I B kinase and 
MAPK pathways.  These pathways subsequently lead towards the activation of JNK (a 
MAPK) and transcription factors NF- B and activation protein 1 (AP-1), which 




Figure 4.1 Overview of LPS/TLR4 signalling. LPS signalling recognition is facilitated by LBP and CD14, 
and is mediated by the TLR4/MD-2 complex.  The LPS/TLR4 signalling can be divided into MyD88 
dependent and MyD88 independent pathways, both of which mediate the activation of pro-inflammatory 







Figure 4.2. The MyD88 dependent pathway. MyD88 activates IRAKs/TRAF6 complex as well as 
transcription factors NF- B, AP-1 and IRF-5.  These transcription factors induce the expression of pro-




The MyD88 independent signalling pathway consists of TRIF, an important mediator of 
the MyD88 independent signalling pathway.  Studies using TRIF-deficient 
macrophages have shown that TRIF plays an important role in the activation of 
transcription factors IRF3, NF- B and MAPK.  The activation of these transcription 
factors results in the induction of type I interferon production (Lu, Yeh, and Ohashi, 
2008) (Figure 4.3). 
TLR 4 is part of a family of toll like receptors, a type of pathogen recognition receptor 
(PRR) that recognises molecules that are broadly shared by pathogens but 
distinguishable from host molecules, collectively referred to as pathogen-associated 
molecular patterns (PAMPs) (Turvey and Broide, 2010).  The TLR family consists of 
10 TLRs (TLR 1 – TLR 10), each of which recognises a different PAMP (Figure 4.4).  
For example, TLR 3 recognises dsRNA and TLR 5 recognises flagellin (Takeda and 
Akira, 2004).  
LPS was chosen to be used in this study because it was very commonly used in   -AR 
transcription and expression studies where an inflammatory state was induced (Heijnen 
et al., 2002; Rouppe van der Voort et al., 2000; Guha and Mackman, 2001).  In this 
project, it was unknown if the LPS had any effect on the activation of the splenocytes as 
cytokine analysis was not performed. However, the unstained negative control that had 
been cultured with LPS did show a profile with much larger cells (high FSC) than the 
unstained non-LPS cells, which is indicative of cellular activation (Figure 3.25) (Teague 









Figure 4.3. The MyD88 independent pathway. TRIF signals the transduction of type I interferons by 
recruiting TRAF4 and RIP1 to activate transcription factors IRF3, AP-1 and NF- B (Adapted from Lu, Yeh, 




Figure 4.4. TLRs and their ligands. Each TLR recognises a different microbial component.  TLR 1 
– 7 and 9 recognise bacterial components.  TLR 9 is the CpG DNA receptor and TLR 3 recognises 





4.4.1.  Lymphocyte Activation via LPS 
 
The introduction of LPS was expected to stimulate naive CD4
+
 T cells with studies 
showing that CD4
+
 cells do express TLR 4 (Gonzalez-Navajas et al., 2010).  Upon 
antigen capture, the APC presents the processed antigen on the MHC II complex to the 
T cell receptor (TCR) on CD4
+
 T cells, resulting in the first stage of activation of CD4
+
 
T cells.  Full activation of CD4
+
 T cells requires co-stimulation of the CD28 molecule 
on CD4
+
 T cells to the CD80 molecule on APCs (Murphy, 2011).   LPS can enhance 
this process however through signalling TLR4 which activates the APC.  Contrary to 
CD8
+
 T cells, direct recognition of LPS was not expected to activate naive CD8
+
 T 
cells, since TLR 4 is not expressed on murine CD8
+
 T cells (Komai-Koma, Gilchrist, 
and Xu, 2009).  Therefore, activation of CD8
+
 T cells occurs through the CD8/MHC I 
interaction and CD28 on the T cell interacting with either CD80 or CD86 on APCs 
(Murphy, 2011).  However co-stimulation from CD4 T cells through cytokine release 
was expected, with this causing the activation of CD8
+
 T cells (Murphy, 2011). 
 
Naive B cells undergo activation through two major pathways: T cell dependent and T 
cell independent activation.  The primary difference between the two pathways is that in 
T cell independent activation, B cells can undergo activation by the binding of an 
antigen to the B cell receptor (BCR), which is enough to initiate activation of the B cell.  
TLR 4 is known to be expressed on B cells and is involved in the activation of naive B 





4.4.2.  Myeloid Cell Activation via LPS 
 
The introduction of LPS was used to activate the myeloid cells.  It has been shown that 
cDCs, macrophages, pDCs and neutrophils all express TLR 4, implying that these cells 
can be directly activated upon exposure to the LPS (Kratky et al., 2011; Richez et al., 
2009; Peyssonnaux et al., 2006; Zheng et al., 2012).  The activation of these cells by 
LPS triggers a release of proinflammatory cytokines including TNF- , IL-6, IL-15 and 
many others (Feghali and Wright, 1997).  The release of cytokines leads to the 
activation of other immune cell types including lymphocytes.   
 
4.5. Expression of   -AR on Lymphoid and Myeloid Cell 
Subsets 
 
There are three   -AR subtypes including    ,    ,    .  While they are found in a 
variety of tissues including cardiac myocytes, endothelial cells and neurons, they are 
also found on immune cells (Piascik and Perez, 2001; Marino and Cosentino, 2013).  
Results from the analysis of   -AR on myeloid cells found that there was a decrease in 
expression of   -ARs on LPS stimulated cells compared to fresh cells.  This conclusion 
was based on data, which showed that the LPS-stimulated myeloid cells had a lower 
geometric MFI of BPr than fresh myeloid cells (Figure 3.29, 3.30, 3.32).  Similar to the 
myeloid populations, there was an observed decrease in geometric MFI of BPr when the 
stimulated lymphocytes were compared to fresh lymphocytes (Figure 3.26, 3.27, 3.28).  
Collectively, these data suggest that in an inflammatory state or at least when the 
immune cells are stimulated, there is a reduction in   -AR protein expression in the 
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lymphocyte and myeloid cell populations identified.  A study using Sprague-Dawley 
rats that had been exposed to LPS to induce endotoxemia examined the mRNA and 
protein expression of all   -AR subtypes (Bucher et al., 2003).  It was observed that 
there was a decrease in all   -AR subtypes and an increase in the cytokines IL-1  and 
TNF- .  It was suggested by the authors that the pro-inflammatory cytokines could have 
potentially mediated the downregulation in expression of the   -AR subtypes.  It should 
be noted however that the study was examining expression of   -AR subtypes in renal 
mesangial cells and not the immune cells themselves. 
Another study examined prazosin treatment and the release of IL-1  before and after 
LPS exposure.  It was discovered while prazosin blocking had no effect on basal plasma 
IL-1  levels, pre-treating cell with prazosin before LPS stimulation could block 
increases in IL-1  levels (Dong et al., 2002).  Another study examining the release of 
TNF-  demonstrated that levels of TNF-  were decreased when mice were given 
prazosin before LPS exposure compared to mice treated with LPS only (Sugino et al., 
2009).  
4.5.1. Expression of   -AR on Myeloid Cells 
One interesting observations is that there was an increase in geometric MFI of BPr in 
LPS stimulated pDCs when compared to fresh pDCs (Figure 3.31).  While the increase 
wasn’t significant (p<0.05), the increase of geometric MFI in pDCs suggests that the 
stimulation of other immune cells led to an increase in cytokine production which 
potentially increased the expression of   -AR.  There is evidence to suggest that 
cytokine production can increase the expression of   -AR.  For example, in human 
THP-1 human monocytes, pro-inflammatory cytokines IL-1  and TNF-  increased the 
mRNA levels of    -AR (Heijnen et al., 2002). 
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It is interesting to note that a radioligand binding study examining the expression of   -
AR on neutrophils found no specific binding for   -AR, suggesting that   -AR 
expression was not detectable on neutrophils (Casale and Kaliner, 1984).  Although no 
detectable   -AR was detected in LPS stimulated neutrophils, the fresh cells displayed 
moderately high geometric MFI for BPr, indicating that there could be expression.  In 
support of this is that there is an observed decrease in the geometric MFI of BPr after 
LPS exposure, indicating the expression of   -AR may have decreased. 
In this study, it was shown that macrophages had no detectable   -AR expression in 
fresh and LPS stimulated cells.  On the contrary, a study showed that macrophages do 
indeed express a functional   -AR (Muthu et al., 2007).  Another study that examined 
macrophages in the rat thymus utilising immunohistochemistry techniques showed   -
AR expression in monocytes and macrophages (Pesic et al., 2009).  While the study was 
looking at monocytes and macrophages located within the thymus, there is a study to 
suggest that   -AR expression is present in both the thymus and spleen (Kavelaars, 
2002). 
There is evidence to suggest that DCs express   -ARs (Maestroni, 2000; Yanagawa, 
Matsumoto, and Togashi, 2010).  However, there is little information about the 







4.5.2. Expression of   -AR on Lymphocytes 
Transcriptional studies have indicated that lymphocytes in the mesenteric lymph nodes 
do express   -AR (Bao et al., 2006).  The same study also showed that stimulation of 
the lymphocytes with a T cell mitogen, concanavalin A (Con-A), increased the quantity 
of   -AR mRNA compared with the resting lymphocytes.  Radioligand binding studies 
using [
3
H]-prazosin has shown that lymphocytes also do express   -AR.  Another study 
used flow cytometry to determine that from isolated rat thymus cells, 11.3% express   -





 (33.2%) T-cells. 
B cells on the contrary have had varied reports on whether   -AR is expressed or not.  
Studies that have used isolated peripheral blood mononuclear cells (PBMCs), which 
contained B cells, have suggested that there is no expression of   -AR on B cells 
(Casale and Kaliner, 1984; Rouppe van der Voort et al., 2000; Tayebati et al., 2000). 
Overall the expression of   -AR on all lymphocytes was low.  The trend however was 
seen across all lymphocytes with a significant decrease (p<0.05) in expression of BPr 
with LPS stimulated lymphocytes displaying lower expression than compared to naive 
lymphocytes.   
The decrease in   -AR expression in fresh lymphocytes to LPS-stimulated lymphocytes 
is perplexing.  However, evidence of expression of   -AR on the LPS-stimulated cells 
indicates that the   -AR may have role in the modulation of the immune response.  A 
study has suggested that the presence of noradrenaline could lead to induction of more 
pro-inflammatory cytokines in activated immune cells (Rouppe van der Voort et al., 
2000). Another study has shown that when lymphocytes were stimulated by Con-A, the 
expression of   -AR mRNA was significantly higher than the resting lymphocytes (Bao 
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et al., 2006).  This suggests that the activation of T cells increased the expression of   -
ARs.   
The impact of the downregulation of   -AR on immune cells could potentially result in 
the lessening of immune cell function and potential response.  In macrophages, it has 
been shown that stimulation of   -AR increases the secretion of TNF-  through a 
cooperative mechanism with TLR4 (Muthu et al., 2007).  The downregulation of   -AR 
could potentially decrease the levels of TNF  and reduce the effectiveness of the 
immune response.  Another study examined the impact of blocking   -AR on the 
development of thymic cells (Pesic et al., 2009).  It was shown that blocking   -ARs 




 T cells, therefore affecting possibly 
the selection stages of T cell development. 
An interesting point to consider is that this study has only examined   -ARs.  Other 
adrenergic receptors such as   -ARs or  -ARs could have potentially caused the 
increase or decrease in   -AR expression.  A study showed culturing human THP-1 
monocytes with the   -AR agonist terbutaline resulted in a rapid rise of     and    -
ARs mRNA but not    -AR mRNA (Kavelaars, 2002).  However, in this project, the 
cells were analysed after 24 hours in LPS which could have potentially allowed for the 
receptors to degrade and be recycled.  Studies examining the turnover rate of   -AR on 
the muscle cell line BC3H-1 have shown that the turnover rate is ~23 to 25 hours 
(Hughes and Insel, 1986; Sladeczek et al., 1984).  
Another point to consider is that only LPS was used in this study to activate immune 
cells.  There could have been better inflammatory stimuli to use.  For instance, a study 
used phytohaemagglutinin, a T cell mitogen, induced   -AR expression in stimulated T 
cells (Rouppe van der Voort et al., 2000).    
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Overall, the project was limited by various reasons.  The use of only one method, flow 
cytometry, limited how much I was able to analyse the cells.  If other methods such as 
PCR were employed in this study, a more accurate result could have been potentially 
achieved.  Another limitation was only examining one subset of ARs, the   -ARs.  
Other receptors such as the   -ARs or  -ARs and subsets could have influenced the 
expression of   -ARs.  The inability to differentiate between the different   -AR 
subsets could have been another possible limitation.     
 
 
4.6. Future Directions 
This study has no doubt raised several interesting questions.  For one, the observed 
decrease in   -AR on all the immune cells examined and how the secretion of cytokines 
may impact the expression of   -AR requires immediate attention.  However due to the 
constraints of time available for the project, this was not possible to do.  The next 
question would be how the expression of   -AR appears in an in vivo model for 
inflammation.    -AR investigations of individual cell populations and tissues provide 
detailed accounts of their expression and possible function.  However, the immune 
system is extremely complex and it is therefore important to know how   -ARs are 
affecting the immune system under physiological conditions in vivo.  Another question 
that is raised is what is the expression of the other ARs including the   -ARs and  -
ARs.  The decrease seen in the results could have been a consequence of cytokine 




In this study, the protein expression of   -ARs was measured on naive or fresh 
splenocytes and compared to the protein expression of   -AR after culturing for 24 
hours in the presence of LPS.  In addition, a modified protocol for optimising BPr has 
been established, producing a titration that shows the optimal titre to stain cells with.  It 
could not be concluded if LPS exposure caused the marked reduction in   -AR protein 
expression.  While stimulation (and therefore induction of inflammation) of immune 
cells was observed, it could have been potentially caused by the effects of cell culturing 
rather than exposure to LPS.  While further aspects need to be studied including 
examining the cytokines produced and expression of the other ARs, the results of this 
project provide preliminary evidence that during the inflammatory state, immune cells 
show a decrease in   -AR with potential ramifications on immune cell function and 
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Appendix A: Reagents List 
 
Reagent Source Catalogue number 
APC Rat Anti-Mouse CD11b BD Pharmingen 553312 
APC Hamster Anti-Mouse CD3e BD Pharmingen 561826 
APC-Cy7 Rat Anti-Mouse CD4 BD Pharmingen 561830 
BV421 Rat Anti-Mouse I-A/I-E BD Horizon 562564 
BV421 Rat Anti-Mouse CD25 BD Horizon 562606 
BV510 Rat Anti-Mouse CD19 BD Horizon 562956 
BV510 Rat Anti-Mouse Ly6G and Ly6C BD Horizon 563040 
Anti-Mouse CD8a PerCP-eFluor710 eBioscience 46-0081 
Anti-Mouse F4/80 Antigen PerCP-Cyanine5.5 eBioscience 45-4801 
PE-Cy7 Hamster Anti-Mouse CD11c BD Pharmingen 558079 
Purified Rat Antu-Mouse CD16/CD32 (Mouse 
BD Fc Block) 
BD Pharmingen 553142 
Lysing Buffer BD Phar Lyse 555899 
LPS from E. coli, Serotype R515 (Re) Enzo ALX-581-007-L002 
Dulbecco’s phosphate buffered saline Sigma-Aldrich D8537 
Foetal bovine serum Invitrogen 10099-141 
RPMI 1640 medium, GlutaMAX supplement ThermoFisher 
Scientific 
61870-036 
Propidium Iodide Staining Solution BD Pharmingen 5556463 
 BODIPY-FL Prazosin ThermoFisher 
Scientific 
B-7433 
 
